var title_f6_43_6832="Transverse fracture of the 5th metacarpal shaft";
var content_f6_43_6832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse fracture of the 5th metacarpal shaft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 487px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transverse fractures of the metacarpal shaft (white arrow) are usually stable.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6832=[""].join("\n");
var outline_f6_43_6832=null;
var title_f6_43_6833="Mebhydrolin: International drug information";
var content_f6_43_6833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mebhydrolin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fabahistin (GB, ZA);",
"     </li>",
"     <li>",
"      Incidal (NL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Mebhydrolin Napadisylate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of allergic symptoms caused by histamine release, including nasal allergies and allergic dermatosis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;10 years and Adults: Oral: 100-300 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 50 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10411 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6833=[""].join("\n");
var outline_f6_43_6833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303438\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979455\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979457\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979460\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979456\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821091\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979459\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10411|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6834="Normal esophagus OCT";
var content_f6_43_6834=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F73005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F73005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal esophagus (optical coherence tomography)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Endoscopic view with optical coherence tomography (OCT) catheter probe placed adjacent to mucosa. (B,C,D) OCT image showing normal histological layers of epithelium (ep), lamina propria (lp), muscularis mucosa (mm), submucosa (sm), and muscularis propria (mp).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shai Friedland, MD and Jacques Van Dam, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6834=[""].join("\n");
var outline_f6_43_6834=null;
var title_f6_43_6835="Basic case 6 with answer";
var content_f6_43_6835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Atrial bigeminy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 125px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atrial bigeminy in which each sinus beat is followed by a premature atrial complex. The premature P waves (arrows) appear to be inverted in lead II, suggesting that they originate from a low atrial ectopic focus. The tall peaked P waves of the sinus beats are consistent with right atrial abnormality (overload).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6835=[""].join("\n");
var outline_f6_43_6835=null;
var title_f6_43_6836="Liver glycogen synthase deficiency (glycogen storage disease 0)";
var content_f6_43_6836=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Liver glycogen synthase deficiency (glycogen storage disease 0)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6836/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6836/contributors\">",
"     William J Craigen, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6836/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6836/contributors\">",
"     Sihoun Hahn, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6836/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6836/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/43/6836/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycogen is the stored form of glucose and serves as a buffer for glucose needs. It is composed of long polymers of a 1-4 linked glucose, interrupted by a 1-6 linked branch point every 4 to 10 residues. Glycogen is formed in periods of dietary carbohydrate loading and broken down when glucose demand is high or dietary availability is low (",
"    <a class=\"graphic graphic_figure graphicRef81164 \" href=\"UTD.htm?4/62/5089\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    There are a number of inborn errors of glycogen metabolism that result from mutations in genes for virtually all of the proteins involved in glycogen synthesis, degradation, or regulation. Those disorders that result in abnormal storage of glycogen are known as glycogen storage diseases (GSDs). They have largely been categorized by number according to the chronology of recognition of the responsible enzyme defect (",
"    <a class=\"graphic graphic_table graphicRef54417 \" href=\"UTD.htm?37/36/38477\">",
"     table 1",
"    </a>",
"    ). The age of onset varies from in utero to adulthood.",
"   </p>",
"   <p>",
"    Glycogen is most abundant in liver and muscle, which are most affected by these disorders. The physiologic importance of a given enzyme in liver and muscle determines the clinical manifestations of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The main role of glycogen in the liver is to store glucose for release to tissues that are unable to synthesize significant amounts during fasting. The major manifestations of disorders of glycogen metabolism affecting the liver are hypoglycemia and hepatomegaly. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"       \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glycogen is the primary source of energy for high-intensity muscle activity by providing substrates for the generation of ATP. The major manifestations of disorders of glycogen metabolism affecting muscle are muscle cramps, exercise intolerance and easy fatigability, and progressive weakness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review liver glycogen synthase deficiency (GSD 0). An overview of glycogen storage disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two isoforms of glycogen synthase have been described. GYS1 is expressed predominantly in skeletal and cardiac muscle, and GYS2 is expressed in the liver. Glycogen-storage disease type 0 (GSD 0, MIM #240600) is caused by a defect in the gene that encodes for liver glycogen synthase (",
"    <em>",
"     GYS2",
"    </em>",
"    ). Liver glycogen synthase deficiency affects the rate-limiting step in glycogen synthesis. A defect in the",
"    <em>",
"     GYS1",
"    </em>",
"    gene is associated with cardiomyopathy and exercise intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel defect in glycogenin-1 (GYG1), a self glycosylating protein that serves to initiate glycogen synthesis, causes a disorder with a paucity of glycogen in muscle tissues and clinical features similar to GYS1 deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/2\">",
"     2",
"    </a>",
"    ]. A defect in the liver isoform GYG2 probably exists, with clinical similarity to GYS2 deficiency, but it has not been reported to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver glycogen synthase deficiency is an autosomal recessive trait with reduced penetrance. Mutations in the",
"    <em>",
"     GYS2",
"    </em>",
"    gene located at 12p12.2 have been reported in familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of liver glycogen synthase deficiency are fasting hypoglycemia, postprandial lactic acidemia, hypoalaninemia, and fasting ketosis. Affected children present with morning fatigue and exhibit ketotic hypoglycemia during fasting that responds to a meal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/6\">",
"     6",
"    </a>",
"    ]. Rare patients may be identified by incidentally observed hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/5\">",
"     5",
"    </a>",
"    ]. Mildly affected or asymptomatic individuals have been identified following diagnosis of a clinically affected family member [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/7\">",
"     7",
"    </a>",
"    ]. While there is often improvement in tolerance to fasting, in untreated patients, long-term complications may include short stature and osteopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver glycogen synthase deficiency is likely underdiagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/8\">",
"     8",
"    </a>",
"    ]. It should be suspected in children with ketotic hypoglycemia after other entities are excluded. In an affected child, typical biochemical findings following a fast are preprandial ketotic hypoglycemia and hypoalaninemia, and postprandial hyperglycemia and lactic acidemia. There may be modest elevations in transaminases and hyperlipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by liver biopsy. Alternatively, mutation analysis of the",
"    <em>",
"     GYS2",
"    </em>",
"    gene can be performed on leukocyte DNA, avoiding the need for liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other biochemical findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glycogen content in liver is low, although not absent",
"     </li>",
"     <li>",
"      Glycogen synthase activity in liver tissue is low or not measurable [",
"      <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Enzyme activity is normal in fibroblasts, which have a different tissue-specific isoform [",
"      <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of liver glycogen synthase deficiency consists of frequent protein-rich meals and avoidance of fasting. Glucose levels can be maintained during sleep in the absence of glycogen degradation by the administration of uncooked cornstarch. Cornstarch is a complex glucose polymer that is slowly digested over a two- to six-hour period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/11\">",
"     11",
"    </a>",
"    ]. Cornstarch may only be required at nighttime; a dose of 1 to 1.5",
"    <span class=\"nowrap\">",
"     gm/kg",
"    </span>",
"    can be used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6836/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liver glycogen synthase deficiency (GSD 0, MIM #240600) affects the rate-limiting step in glycogen synthesis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver glycogen synthase deficiency is an autosomal recessive trait with reduced penetrance. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Affected children may present with morning fatigue. Laboratory features include fasting hypoglycemia, postprandial lactic acidemia, hyperglycemia, hypoalaninemia, and fasting ketosis. Long-term complications may include short stature and osteopenia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver glycogen synthase deficiency should be suspected in children with ketotic hypoglycemia after other entities are excluded. The diagnosis is confirmed by liver biopsy or mutation analysis for the",
"      <em>",
"       GYS2",
"      </em>",
"      gene in leukocyte DNA. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment consists of frequent protein-rich meals and avoidance of fasting. Glucose levels can be maintained during sleep by the administration of uncooked cornstarch. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/1\">",
"      Kollberg G, Tulinius M, Gilljam T, et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med 2007; 357:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/2\">",
"      Moslemi AR, Lindberg C, Nilsson J, et al. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N Engl J Med 2010; 362:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/3\">",
"      Orho M, Bosshard NU, Buist NR, et al. Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest 1998; 102:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/4\">",
"      Weinstein DA, Correia CE, Saunders AC, Wolfsdorf JI. Hepatic glycogen synthase deficiency: an infrequently recognized cause of ketotic hypoglycemia. Mol Genet Metab 2006; 87:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/5\">",
"      Spiegel R, Mahamid J, Orho-Melander M, et al. The variable clinical phenotype of liver glycogen synthase deficiency. J Pediatr Endocrinol Metab 2007; 20:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/6\">",
"      Aynsley-Green A, Williamson DH, Gitzelmann R. Hepatic glycogen synthetase deficiency. Definition of syndrome from metabolic and enzyme studies on a 9-year-old girl. Arch Dis Child 1977; 52:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/7\">",
"      Aynsley-Green A, Williamson DH, Gitzelmann R. Asymptomatic hepatic glycogen synthetase deficiency (Letter). Lancet 1978; I:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/8\">",
"      Gitzelmann R, Spycher MA, Feil G, et al. Liver glycogen synthase deficiency: a rarely diagnosed entity. Eur J Pediatr 1996; 155:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/9\">",
"      Bachrach BE, Weinstein DA, Orho-Melander M, et al. Glycogen synthase deficiency (glycogen storage disease type 0) presenting with hyperglycemia and glucosuria: report of three new mutations. J Pediatr 2002; 140:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/10\">",
"      Gitzelmann R, Steinmann B, Aynsley-Green A. Hepatic glycogen synthetase deficiency not expressed in cultured skin fibroblasts. Clin Chim Acta 1983; 130:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6836/abstract/11\">",
"      Chen YT, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 1984; 310:171.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2947 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6836=[""].join("\n");
var outline_f6_43_6836=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2947\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2947|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/62/5089\" title=\"figure 1\">",
"      Pathways of glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2947|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/36/38477\" title=\"table 1\">",
"      Disorders of glycogen - glucose metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6837="Cabergoline: Patient drug information";
var content_f6_43_6837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cabergoline: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     see \"Cabergoline: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Cabergoline;",
"     </li>",
"     <li>",
"      Dostinex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat some prolactin-secreting tumors.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cabergoline or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703864",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart valve problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the heart valve may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime to stop upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11592 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-EBA391572F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6837=[""].join("\n");
var outline_f6_43_6837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143938\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029018\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029020\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029019\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029024\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029025\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029027\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029022\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029023\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029028\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029029\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=related_link\">",
"      Cabergoline: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6838="HBV risk map";
var content_f6_43_6838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62806&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Prevalence of chronic infection with hepatitis B virus, 2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from:&nbsp;",
"     <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm\">",
"      file://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-b.htm",
"     </a>",
"     . (accessed on July 11, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6838=[""].join("\n");
var outline_f6_43_6838=null;
var title_f6_43_6839="Abacavir, lamivudine, and zidovudine: Pediatric drug information";
var content_f6_43_6839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abacavir, lamivudine, and zidovudine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10918?source=see_link\">",
"    see \"Abacavir, lamivudine, and zidovudine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/34/42533?source=see_link\">",
"    see \"Abacavir, lamivudine, and zidovudine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trizivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7792786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Trizivir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1050723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1050715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10918?source=see_link\">",
"      see \"Abacavir, lamivudine, and zidovudine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adolescents &lt;40 kg: Not recommended; product is a fixed-dose combination",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;40 kg and Adults: 1 tablet twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Use not recommended (use individual antiretroviral agents to reduce dosage)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use is contraindicated; use individual antiretroviral agents to reduce dosage.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F128854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Trizivir&reg;: Abacavir sulfate 300 mg, lamivudine 150 mg, and zidovudine 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F128840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089807.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089807.pdf",
"     </a>",
"     , must be dispensed with this medication. A Warning Card (summarizing symptoms of hypersensitivity), which is available with the product information, must also be dispensed with this medication for each new outpatient prescription and refill.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1050726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1050718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1050725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection, either alone or in combination with other antiretroviral agents (FDA approved in adolescents &ge;40 kg and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended;",
"     <b>",
"      Note:",
"     </b>",
"     Data on the use of this triple NRTI combination regimen in patients with baseline viral loads &gt;100,000 copies/mL is limited.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F128892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatal hypersensitivity reactions have occurred in patients taking abacavir (in Trizivir&reg;). If Trizivir&reg; is to be restarted following an interruption in therapy, first evaluate the patient for previously unsuspected symptoms of hypersensitivity. Do not restart if hypersensitivity is suspected or if hypersensitivity cannot be ruled out.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     The following information is based on CNA3005 study data concerning effects noted in patients receiving abacavir, lamivudine, and zidovudine. See individual agents for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, fatigue, fever/chills, headache, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Amylase increased, diarrhea, GGT increased, nausea, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Neutropenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: CPK increased",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear infection",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nose/throat infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity, viral infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1050729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to abacavir, lamivudine, zidovudine, or any component; hepatic impairment.",
"     <b>",
"      Do not rechallenge",
"     </b>",
"     patients who have experienced hypersensitivity reactions to abacavir (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status), potentially fatal hypersensitivity reactions may occur",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1050714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of abacavir has been associated with an increased risk of myocardial infarction (MI) in observational studies; however, based on a meta-analysis of 26 randomized trials with abacavir therapy, the FDA has concluded there is not an increased risk. Consider using with caution in patients with risks for coronary heart disease and minimizing modifiable risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, and smoking) prior to use. HIV therapy-experienced patients may have a lower response to the abacavir component.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established). Resistance to abacavir develops relatively slowly, but cross resistance between abacavir and other nucleoside reverse transcriptase inhibitors (NRTIs) may occur; limited response may be seen in patients with HIV isolates containing multiple mutations conferring resistance to NRTIs or in patients with a prolonged prior NRTI exposure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Grave&rsquo;s disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Do not administer Trizivir&reg; with abacavir, lamivudine, or zidovudine-containing products (eg, Epivir&reg;, Combivir&reg;, Epzicom&reg;, or Ziagen&reg;) or emtricitabine-containing products (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, or Truvada&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1050713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and sometimes fatal hypersensitivity reactions to abacavir may occur",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Patients testing positive for the presence of the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele are at a significantly increased risk for hypersensitivity reactions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Screening for",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele status is recommended prior to initiating therapy or reinitiating therapy in patients of unknown genotype status, including patients who previously tolerated therapy. Patients who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele should have an abacavir allergy recorded in their medical record and should",
"     <b>",
"      not",
"     </b>",
"     receive abacavir. If a suspected abacavir hypersensitivity reaction occurs during therapy, regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status, abacavir should be discontinued immediately and permanently.  Hypersensitivity reactions may also occur in patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele, but at a significantly lower rate.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Abacavir hypersensitivity is a multiorgan clinical syndrome",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Discontinue therapy immediately in patients who show signs or symptoms of 2 or more of the following: Fever, skin rash, respiratory symptoms (including cough, dyspnea, or pharyngitis) and GI symptoms (including nausea, vomiting, diarrhea, or abdominal pain), and constitutional symptoms (including fatigue, malaise, or achiness). Carefully consider the diagnosis of hypersensitivity reaction in patients who present with acute onset respiratory symptoms, even if other diagnoses, such as bronchitis, flu-like illness, pharyngitis, or pneumonia, are possible. Permanently discontinue abacavir-containing medications if hypersensitivity reaction cannot be ruled out, even when other diagnoses are possible (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Skin rash may be maculopapular or urticarial, but can be variable in appearance; erythema multiforme has been reported; hypersensitivity reaction may occur without a rash. Other symptoms may include edema, lethargy, myolysis, paresthesia, shortness of breath, mouth ulcerations, conjunctivitis, lymphadenopathy, and abnormal findings on chest x-ray (ie, infiltrates that can be localized). Anaphylaxis, renal failure, hepatic failure, respiratory failure, ARDS, hypotension, and death may also occur in association with hypersensitivity reactions. Laboratory abnormalities include increases in liver function tests, elevated CPK or serum creatinine, and lymphopenia.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Do not restart",
"     </b>",
"     abacavir, Trizivir&reg;, or any other abacavir-containing product after a hypersensitivity reaction occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; more severe symptoms can recur within hours and may include life-threatening hypotension and death. Fatal hypersensitivity reactions have occurred following the reintroduction of abacavir in patients whose therapy was interrupted for other reasons",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . These patients had no identified history or had unrecognized symptoms of abacavir hypersensitivity. Reactions occurred within hours. In some cases, signs of a hypersensitivity reaction may have been previously present, but attributed to other medical conditions (acute onset respiratory diseases, gastroenteritis, reactions to other medications). If abacavir, Trizivir&reg;, or any other abacavir-containing product is to be restarted following an interruption in therapy, the patient must first be evaluated for previously unsuspected symptoms of hypersensitivity.",
"     <b>",
"      Do not restart",
"     </b>",
"     abacavir, Trizivir&reg;, or any other abacavir-containing product if hypersensitivity is suspected or cannot be ruled out (regardless of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status). Hypersensitivity reactions occur in 5% to 8% of adult and pediatric patients (actual incidence varies by race/ethnicity); most hypersensitivity reactions occur within the first 6 weeks of therapy, but can occur at any time.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported in patients receiving nucleoside analogues",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue Trizivir&reg; in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     The major clinical toxicity of lamivudine in pediatric patients is pancreatitis; discontinue therapy if clinical signs, symptoms, or laboratory abnormalities suggestive of pancreatitis occur. HIV-infected patients who are coinfected with hepatitis B may experience severe acute exacerbations and clinical symptoms or laboratory evidence of hepatitis when a lamivudine-containing medication is discontinued",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most cases are self-limited, but fatalities have been reported; monitor patients closely for at least several months after discontinuation of abacavir, lamivudine, and zidovudine; initiation of antihepatitis B therapy may be required.",
"     <b>",
"      Note:",
"     </b>",
"     HIV-infected patients should be screened for hepatitis B infection prior to starting lamivudine therapy. Concomitant use of combination antiretroviral therapy with interferon alfa (with or without ribavirin) has resulted in hepatic decompensation (with some fatalities) in patients coinfected with HIV and HCV; monitor patients closely, especially for hepatic decompensation, neutropenia, and anemia; consider discontinuation of abacavir, lamivudine, and zidovudine if needed; consider dose reduction or discontinuation of interferon alfa, ribavirin, or both if clinical toxicities, including hepatic decompensation, worsen.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Zidovudine is associated with hematologic toxicity including granulocytopenia and severe anemia requiring transfusions",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use with caution in patients with ANC &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or hemoglobin &lt;9.5 g/dL; consider interruption of therapy for significant anemia (Hgb &lt;7.5 g/dL or reduction &gt;25% of baseline) or neutropenia (ANC &lt;750 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     or reduction &gt;50% from baseline); use of erythropoietin or filgrastim may be necessary in some patients; prolonged use of zidovudine may cause myositis and myopathy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Trizivir&reg; contains abacavir, lamivudine, and zidovudine as a fixed-dose combination; do not use in patients weighing &lt;40 kg, in patients with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute) who require lamivudine and zidovudine dosage adjustment, or in patients with hepatic dysfunction. Patients with mild to moderate hepatic dysfunction or liver cirrhosis require zidovudine dosage adjustment; abacavir is contraindicated in patients with moderate to severe hepatic dysfunction; patients with mild hepatic impairment require abacavir dosage reduction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F128848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May enhance the CNS depressant effect of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: May enhance the myelosuppressive effect of Zidovudine. Clarithromycin may decrease the serum concentration of Zidovudine. Management: Monitor response to zidovudine closely when used with clarithromycin, and consider staggering zidovudine and clarithromycin doses when possible in order to minimize the potential for interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin: May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOXOrubicin (Liposomal): May enhance the adverse/toxic effect of Zidovudine. DOXOrubicin (Liposomal) may diminish the therapeutic effect of Zidovudine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Emtricitabine: LamiVUDine may enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons: May enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: May increase the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Zidovudine may enhance the adverse/toxic effect of Ribavirin. Specifically, the risk/severity of anemia may be increased.  Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin.  Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Zidovudine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stavudine: Zidovudine may diminish the therapeutic effect of Stavudine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of LamiVUDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1050732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food decreases the rate, but not the extent of absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F128850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F128863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1050722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     genotype status prior to initiating therapy or resuming therapy in patients of unknown",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     status (including patients previously tolerating therapy); signs and symptoms of abacavir hypersensitivity reaction (in all patients, but especially in those untested for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine.  At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphate, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, hepatotoxicity, anemia, pancreatitis, or lactic acidosis; serum creatine kinase",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1050712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1050728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One Trizivir&reg; tablet is bioequivalent, in the extent (AUC) and rate of absorption (peak concentration and time to peak concentration), to one abacavir 300 mg tablet, one lamivudine 150 mg tablet, plus one zidovudine 300 mg tablet; see individual agents",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1050720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/34/42533?source=see_link\">",
"      see \"Abacavir, lamivudine, and zidovudine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Trizivir&reg; is not a cure for HIV. Take Trizivir&reg; every day as prescribed; do not change dose or discontinue without physician's advice. If Trizivir&reg; is stopped for any reason, notify physician before restarting therapy. If a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do",
"     <b>",
"      not",
"     </b>",
"     double the next dose. Avoid alcohol. Notify physician if persistent severe abdominal pain, nausea, or vomiting occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Trizivir&reg; contains abacavir (also called Ziagen&reg;). Abacavir may cause serious and sometimes fatal allergic (hypersensitivity) reaction. Read the Patient Medication Guide that you receive with each prescription and refill of abacavir, lamivudine, and zidovudine. Stop taking Trizivir&reg; and notify physician immediately if 2 or more of the following sets of symptoms occur: Fever, rash, GI symptoms (nausea, vomiting, diarrhea, or abdominal pain), flu-like symptoms (severe tiredness, achiness, or generally ill feeling), or respiratory symptoms (sore throat, shortness of breath, cough). If you experience an allergic (hypersensitivity) reaction to Trizivir&reg; (or abacavir, Ziagen&reg;, or Epzicom&reg;),",
"     <b>",
"      never",
"     </b>",
"     take Trizivir&reg;, abacavir, Ziagen&reg;, or Epzicom&reg; again.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Trizivir&reg; contains zidovudine which may cause a decrease in white blood cells or red blood cells (anemia); routine blood tests can help detect these blood problems. Zidovudine may also cause muscle weakness with prolonged use, which may be a serious problem; notify physician if muscle weakness occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including abacavir, lamivudine, and zidovudine) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Before starting Trizivir&reg;, inform your physician about your medical conditions, including any blood, kidney, heart, or liver problems (including hepatitis B infection), if you smoke, or have diabetes, high cholesterol, or high blood pressure. Do not take Trizivir&reg; with abacavir, lamivudine, or zidovudine-containing products (eg, Epivir&reg;, Combivir&reg;, Epzicom&reg;, or Ziagen&reg;) or emtricitabine-containing products (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, or Truvada&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1050730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The development of the abacavir hypersensitivity reaction has been associated with certain HLA genotypes (eg,",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     ,",
"     <i>",
"      HLA-DR7",
"     </i>",
"     ,",
"     <i>",
"      HLA-DQ3",
"     </i>",
"     ) which may help predict which patients are at risk for developing the abacavir hypersensitivity reaction (Hetherington, 2002; Lucas, 2007; Mallal, 2002). Patients who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele should have an abacavir allergy recorded in their medical record and should",
"     <b>",
"      not",
"     </b>",
"     receive abacavir. All patients who receive abacavir (and their caregivers) should be educated about the risk of abacavir hypersensitivity reactions (including patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele, as the risk for the reaction is not completely eliminated). Approximately 4% of patients who test negative for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele will experience a clinically suspected abacavir hypersensitivity reaction compared to 61% of those who test positive for the",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     allele.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The prevalence of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     in the United States has been estimated to be 8% in Caucasians, 2.5% in African-Americans, 2% in Hispanics, 1% in Asians; in the sub-Saharan Africa it is &lt;1%. Pretherapy identification of",
"     <i>",
"      HLA-B*5701",
"     </i>",
"     -positive patients and subsequent avoidance of abacavir therapy in these patients has been shown to significantly reduce the occurrence of abacavir-associated hypersensitivity reactions. A skin patch test is in development for clinical screening purposes; however, only PCR-mediated genotyping methods are currently in clinical practice use for documentation of this susceptibility marker. A familial predisposition to the abacavir hypersensitivity reaction has been reported; use abacavir with great caution in children of parents who experience a hypersensitivity reaction to abacavir (Peyri&eacute;re, 2001).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Reverse transcriptase mutations of K65R, L74V, Y115F, and M184V have been associated with abacavir resistance; at least 2-3 mutations are needed to decrease HIV susceptibility by 10-fold. The presence of a multiple number of these abacavir resistance-associated mutations may confer cross-resistance for other nucleoside or nucleotide reverse transcriptase inhibitors (eg, didanosine, emtricitabine, lamivudine, zalcitabine, or tenofovir). A progressive decrease in abacavir susceptibility is associated with an increasing number of thymidine analogue mutations (TAMs; M41L, D67N, K70R, L210W, T215Y/F, K219E/R/H/Q/N).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" Februray 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hetherington S, Hughes AR, Mosteller M, et al, \"Genetic Variations in HLA-B Region and Hypersensitivity Reactions to Abacavir,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9312):1121-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/43/6839/abstract-text/ 11943262 /pubmed\" id=\" 11943262 \" target=\"_blank\">",
"        11943262",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lucas A, Nolan D, and Mallal S, \"HLA-B*5701 Screening for Susceptibility to Abacavir Hypersensitivity,\"",
"      <i>",
"       J Antimicrob Chemother",
"      </i>",
"      , 2007, 59(4):591-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/43/6839/abstract-text/17317695/pubmed\" id=\"17317695\" target=\"_blank\">",
"        17317695",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mallal S, Nolan D, Witt C, et al, \"Association Between Presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and Hypersensitivity to HIV-1 Reverse-Transcriptase Inhibitor Abacavir,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9308):727-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/43/6839/abstract-text/11888582/pubmed\" id=\"11888582\" target=\"_blank\">",
"        11888582",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peyri&eacute;re H, Nicolas J, Siffert M, et al, &ldquo;Hypersensitivity Related to Abacavir in Two Members of a Family,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2001, 35(10):1291-2.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saez-Llorens X, Nelson RP, Emmanuel P, et al, \"A Randomized, Double-Blind Study of Triple Nucleoside Therapy of Abacavir, Lamivudine, and Zidovudine Versus Lamivudine and Zidovudine in Previously Treated Human Immunodeficiency Virus Type 1-Infected Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 107(1). Available at file://www.pediatrics.org/cgi/content/full/107/1/e4",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/43/6839/abstract-text/11134468/pubmed\" id=\"11134468\" target=\"_blank\">",
"        11134468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13185 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-88.81.100.162-2094B74F85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6839=[""].join("\n");
var outline_f6_43_6839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708609\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128871\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7792786\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050723\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050715\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128854\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128840\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874273\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050726\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050718\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050725\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128892\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050729\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050714\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050713\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298626\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128848\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050732\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128850\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128863\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050722\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050712\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050728\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050720\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1050730\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13185|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10918?source=related_link\">",
"      Abacavir, lamivudine, and zidovudine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/34/42533?source=related_link\">",
"      Abacavir, lamivudine, and zidovudine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6840="Skin nodules in newborns and infants";
var content_f6_43_6840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Skin nodules in newborns and infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Josie A Pielop, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6840/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/43/6840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of cutaneous and subcutaneous nodules may be detected in the newborn. Most are benign and self-limited, such as cysts, subcutaneous fat necrosis, and certain soft tissue tumors. However, some may be because of malignancy or be a marker for other abnormalities, such as neural tube defects.",
"   </p>",
"   <p>",
"    Cysts, subcutaneous fat necrosis, and tumors that present at birth or in early infancy are reviewed here. Other benign skin lesions, vesiculopustular and bullous disorders, and congenital pigmented and vascular disorders in the newborn are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=see_link\">",
"     \"Benign skin and scalp lesions in the newborn and young infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link\">",
"     \"Vascular lesions in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"     \"Vesiculobullous and pustular lesions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CYSTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common types of cysts include dermoid cysts and epidermal cysts. Other types, such as branchial cleft or thyroglossal duct cysts, may also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dermoid cysts and sinuses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dermoid cysts are congenital subcutaneous lesions that are usually distributed along embryonic fusion lines of the facial processes or within the neural axis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/1\">",
"     1",
"    </a>",
"    ]. The most common locations are overlying the anterior fontanelle, the bregma (junction of the coronal and sagittal sutures), upper lateral region of the forehead, lateral upper eyelid, and submental region, although lesions can occur anywhere on the scalp, face, spinal axis, or other body sites.",
"   </p>",
"   <p>",
"    Dermoid cysts are almost always present at birth, although subtle lesions may not be noticed until, for example, trauma causes inflammation (",
"    <a class=\"graphic graphic_picture graphicRef73660 \" href=\"UTD.htm?20/20/20803\">",
"     picture 1",
"    </a>",
"    ). They present as small (1 to 4 cm in diameter), slow-growing, asymptomatic rubbery subcutaneous nodules that are usually solitary (",
"    <a class=\"graphic graphic_picture graphicRef61893 \" href=\"UTD.htm?31/51/32564\">",
"     picture 2",
"    </a>",
"    ). They are nonpulsatile, noncompressible, nontender masses that appear skin-colored or blue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/1\">",
"     1",
"    </a>",
"    ]. The skin overlying the cyst appears normal unless a pit or a sinus is present.",
"   </p>",
"   <p>",
"    The characteristic histologic findings include a lining of epidermis and evidence of adnexal structures, such as hair follicles, sebaceous glands, and eccrine and apocrine sweat apparatus. Foci of keratinization and sometimes mesodermal skin components may be present. These features distinguish dermoid cysts from epidermoid cysts. The latter typically appear later in life on the trunk and extremities. They generally are intradermal and do not uniformly contain hair follicles and sebaceous glands.",
"   </p>",
"   <p>",
"    Dermal sinus tracts may connect cysts to the skin surface or to underlying structures such as the bone, central nervous system (CNS), or paranasal sinuses. Cutaneous sinuses are one to five mm in length and may have a small tuft of hair protruding from the orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/1\">",
"     1",
"    </a>",
"    ]. Connections to the CNS are most frequent with midline or nasal dermoid cysts, occurring in approximately 25 percent of cases. A pit or sinus is associated with approximately one-half of nasal dermoid cysts. Midline lesions, most commonly in the lumbosacral region, are often markers of spinal dysraphism, including a tethered cord [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sinus tracts to the skin are usually detected when they become infected and drain purulent material. If the sinus or cyst communicates with the CNS, cerebrospinal fluid may drain from the lesion. This connection also allows entry of bacteria, and may be detected in a patient presenting with meningitis caused by unusual organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with midline lesions should be evaluated with neuroimaging to detect CNS connections or underlying spinal dysraphism. Patients with findings on neuroimaging or other clinical abnormalities should be referred to a neurosurgeon.",
"   </p>",
"   <p>",
"    Dermoid cysts should be surgically excised because of the risk of associated complications; the timing of excision depends upon the site and any associated findings. The most common complication is infection, including meningitis in lesions that connect to the CNS. In addition, the cysts may adhere to the periosteum or erode underlying skull [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Nasal dermoids typically enlarge, resulting in damage to the nasal bones. Malignant degeneration can occur but is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Other cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroglossal duct cysts are the most common form of congenital cyst in the neck. They are cysts of epithelial remnants of the thyroglossal tract and present characteristically as a midline neck mass at the level of the thyrohyoid membrane, closely associated with the hyoid bone. Affected patients should be referred for surgical excision of the cyst if there is infection or persistent drainage. If the size of the lesion and thyroid function are not problems, they can be followed clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=see_link\">",
"     \"Thyroglossal duct cysts and ectopic thyroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Branchial cleft cysts usually arise from the first and second branchial arches. They are commonly located anterior to the sternocleidomastoid muscle on the lower third of the lateral neck (",
"    <a class=\"graphic graphic_picture graphicRef59067 \" href=\"UTD.htm?26/48/27392\">",
"     picture 3",
"    </a>",
"    ). The cysts often contain lymphoid tissue. Third branchial cleft cysts are found at the head of the clavicles.",
"   </p>",
"   <p>",
"    Epidermal cysts result when epidermal cells located within the dermis proliferate and do not communicate with the surface. They can arise from occluded pilosebaceous follicles, entrapment of epidermal cells along embryonic lines of closures, or traumatic displacement of epidermal cells into the dermis. Epidermal cysts usually develop after puberty, although some present in the newborn period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/8\">",
"     8",
"    </a>",
"    ]. Examples in newborns include milia and median raphe cysts. Their histologic appearance may be similar to dermoid cysts or they may contain stratified squamous epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SUBCUTANEOUS FAT NECROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous fat necrosis (SFN) is a rare condition that affects newborns in the first few weeks of life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. It typically affects term or postterm newborns and usually follows perinatal complications such as birth asphyxia, hypothermia, meconium aspiration syndrome, newborn failure to thrive, forceps delivery, and maternal high blood pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Cases have been reported following neonatal cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. One case series identified possible additional risk factors, including macrosomia; exposure to active or passive smoking during pregnancy; and maternal, paternal, or newborn risk factors for thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features of SFN include multiple firm nontender subcutaneous nodules or large plaques that appear one to four weeks after birth. Commonly affected sites are the cheeks, buttocks, back, and limbs. It often occurs over bony prominences. The anterior trunk tends to be spared. The overlying skin may be erythematous. Lesions may become fluctuant as fat liquefies; some become calcified. SFN usually resolves completely within one to two months, although it may persist up to six months, especially when lesions are calcified.",
"   </p>",
"   <p>",
"    The histologic appearance of the lesions is a granulomatous reaction in the fat [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/15\">",
"     15",
"    </a>",
"    ]. This includes foreign body giant cells, lymphocytes, histiocytes, and fibroblasts; needle-shaped clefts are seen within the histiocytes and giant cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/16\">",
"     16",
"    </a>",
"    ]. Fibrosis develops as the lesions resolve.",
"   </p>",
"   <p>",
"    SFN should be differentiated from sclerema neonatorum (SN), which also occurs during the first few months after birth (",
"    <a class=\"graphic graphic_table graphicRef70556 \" href=\"UTD.htm?1/7/1148\">",
"     table 1",
"    </a>",
"    ). SN is characterized by the presence of diffuse, waxlike hardening of the subcutaneous adipose tissue, in which the skin is bound to the underlying muscle and bone, resulting in respiratory and feeding difficulties and flexion contractures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/15,17,18\">",
"     15,17,18",
"    </a>",
"    ]. Affected newborns are often preterm and severely ill, with a poor prognosis. In contrast to the histology of SFN, there is minimal subcutaneous inflammation, prominent thickening of the trabeculae supporting the subcutaneous adipose tissue and an absence of fat necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypercalcemia is a serious complication that has been associated with some cases of SFN, although the frequency is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. Affected infants may present with irritability, anorexia, constipation, and failure to thrive. Seizures, renal failure, and cardiac arrest can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/10,19\">",
"     10,19",
"    </a>",
"    ]. The mechanism of hypercalcemia associated with SFN is unknown. One hypothesis is that intestinal calcium uptake is stimulated by 1,25(OH)2D3 that is stimulated by macrophages present in the infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/10\">",
"     10",
"    </a>",
"    ]. Reported treatments for severe hypercalcemia in infants with subcutaneous fat necrosis have included hydration,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , corticosteroids, and bisphosphonates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypocalcemia in association with subcutaneous fat necrosis also has been described in a case report [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/22\">",
"     22",
"    </a>",
"    ]. This patient was treated with vitamin D analogs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=see_link\">",
"     \"Neonatal hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other infrequent complications of subcutaneous fat necrosis of the newborn include thrombocytopenia and hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/10,23-28\">",
"     10,23-28",
"    </a>",
"    ]. Thrombocytopenia typically appears before or simultaneously with the cutaneous lesions and resolves spontaneously over the next days to weeks. The cause of thrombocytopenia is not known; sequestration of platelets within the subcutaneous tissue has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of SFN is expectant, as most lesions resolve spontaneously. Scarring may be diminished if calcified lesions are drained [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/15\">",
"     15",
"    </a>",
"    ]. Infants should be closely monitored for the development of hypercalcemia. Serum calcium concentration should be measured at least every other week; in extensive cases, a calcium level should be drawn weekly.",
"   </p>",
"   <p>",
"    In extensive cases, serum calcium concentration should be measured at least biweekly for up to six months or until the lesions clinically resolve .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of soft tissue tumors present at birth or during the first year of life. In one report, 20 percent of a series of these tumors in children presented in this period [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/29\">",
"     29",
"    </a>",
"    ]. More than 75 percent were pathologically benign. The most common benign tumors were hemangiomas and vascular malformations. Malignancies affecting the skin, such as infantile fibrosarcoma, rhabdomyosarcoma, neuroblastoma, and congenital leukemia are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benign tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign soft tissue tumors in newborns and infants include infantile hemangiomas, vascular malformations, infantile myofibromatosis, congenital self-healing reticulohistiocytosis, and cutaneous mastocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Infantile hemangiomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile hemangiomas are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Vascular lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital vascular lesions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=see_link\">",
"     \"Vascular lesions in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Infantile myofibromatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile myofibromatosis, formerly known as congenital fibromatosis, is the most common fibrous tumor of infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/30\">",
"     30",
"    </a>",
"    ]. In two series, 90 percent were detected during the first year of life, with 60 percent found at birth or soon after [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The condition occurs in two forms, solitary (the more frequent type) and multicentric. In the solitary form, a single lesion affecting the skin or muscle is present, most commonly on the head, neck, or trunk. Solitary lesions are more likely to occur in males (69 percent of cases in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/32\">",
"     32",
"    </a>",
"    ]. Multiple lesions are present in the multicentric form, which may affect bones and viscera as well as soft tissues. The multicentric form is more common in females (63 percent of cases) and is more likely to be congenital [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course is usually benign in infants with soft tissue lesions and no visceral involvement; lesions usually spontaneously involute within one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. However, the condition may be fatal in infants with the multicentric form and extensive visceral involvement, especially of the lung.",
"   </p>",
"   <p>",
"    The superficial lesions are rubbery and firm rounded nodules and may be mobile (",
"    <a class=\"graphic graphic_picture graphicRef71251 graphicRef61534 graphicRef50300 \" href=\"UTD.htm?25/21/25945\">",
"     picture 4A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/34\">",
"     34",
"    </a>",
"    ]. The deeper lesions are nonmobile. They range in diameter from 1 to 7 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/32\">",
"     32",
"    </a>",
"    ]. In some cases, the overlying skin has a red or purple discoloration which may mimic a hemangioma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=see_link\">",
"     \"Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histologic appearance is similar in solitary and multiple cutaneous and visceral lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/35\">",
"     35",
"    </a>",
"    ]. There are well-circumscribed masses of spindle-shaped cells staining as fibroblasts or smooth muscle cells, bland necrosis with stippled calcification, and plentiful thin-walled vessels. Atypia is uniformly absent.",
"   </p>",
"   <p>",
"    The diagnosis of the multicentric form of infantile myofibromatosis is usually made on the basis of clinical features and characteristic histopathology. A radiographic survey should be performed to detect osseous lesions. The diagnosis of the solitary form is made by biopsy to distinguish it from fibrosarcoma, leiomyoma-leiomyosarcoma, hemangiopericytoma, and neurofibroma.",
"   </p>",
"   <p>",
"    Close observation of these tumors is often appropriate for solitary or multiple soft tissue lesions without visceral involvement because of the high rate of spontaneous regression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/34\">",
"     34",
"    </a>",
"    ]. Visceral myofibromas or tumors that affect function are surgically excised. Recurrence is unusual and can be managed by reexcision or treated with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Congenital self-healing reticulohistiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital self-healing reticulohistiocytosis (CSHR, Hashimoto-Pritzker disease) is a benign tumor that is a variant of Langerhans cell histiocytosis. It presents at birth or in the newborn period as solitary (25 percent of cases) or multiple cutaneous nodules that may be located anywhere on the infant (",
"    <a class=\"graphic graphic_picture graphicRef75074 \" href=\"UTD.htm?29/28/30146\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/37\">",
"     37",
"    </a>",
"    ]. The nodules often centrally ulcerate either before or shortly after birth (",
"    <a class=\"graphic graphic_picture graphicRef56146 \" href=\"UTD.htm?16/39/17010\">",
"     picture 6",
"    </a>",
"    ). Vesicles and bullae have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/38\">",
"     38",
"    </a>",
"    ]. All lesions heal within a few months, sometimes leaving an atrophic white scar. Due to the high rate of spontaneous resolution and lack of clinical recognition, the incidence of CSHR is likely underestimated in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis is confirmed by the characteristic histologic appearance on skin biopsy. This shows proliferation of large mononuclear cells resembling Langerhans cells that stain positively for S-100. Characteristic features seen on electron microscopy are dense bodies, regularly laminated bodies, and Birbeck granules. These features distinguish CSHR from other neonatal lesions such as dermoid cysts, pilomatricomas, congenital Spitz nevus, infantile myofibromatosis, and congenital fibrosarcoma.",
"   </p>",
"   <p>",
"    Malignant forms of histiocytosis are excluded by the presence of three criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of extracutaneous involvement",
"     </li>",
"     <li>",
"      Resolution of cutaneous disease",
"     </li>",
"     <li>",
"      Absence of recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunohistochemical stains such as E-cadherin, Ki-67, and phosphorylated histone H3 have not been shown to reliably distinguish CSHR from disseminated Langerhans cell histiocytosis with cutaneous involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/39\">",
"     39",
"    </a>",
"    ]. Confinement of disease to the skin is investigated by performing a complete blood count, coagulation studies, serum chemistries, liver function tests, urine osmolality, chest and bone radiographs, abdominal ultrasound, and bone marrow biopsy if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/40\">",
"     40",
"    </a>",
"    ]. It is essential that affected patients are followed closely because of the possibility of recurrence and, in rare cases, of disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=see_link&amp;anchor=H452648848#H452648848\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis\", section on 'Skin and oral mucosa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Cutaneous mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous mastocytomas are rare lesions composed of mast cells that occur in childhood (",
"    <a class=\"graphic graphic_picture graphicRef76891 graphicRef50284 \" href=\"UTD.htm?25/42/26279\">",
"     picture 7A-B",
"    </a>",
"    ). They may be solitary or multiple. Manipulation of the lesion by rubbing or pressure may trigger mast cell mediator release with resultant flushing and occasionally hypotension. In most cases, the caretakers have noticed this phenomenon and can describe it, without the need to disturb the lesion and induce symptoms. Cutaneous mastocytomas typically regress spontaneously by adolescence. Cutaneous and systemic mastocytosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Malignant tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant tumors affecting the skin that present at birth or in the neonatal period are rare. Examples include infantile fibrosarcoma, rhabdomyosarcoma, neuroblastoma, and congenital leukemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Infantile fibrosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile fibrosarcoma is a rapidly growing poorly circumscribed spindle cell tumor of the soft tissues that may present at birth or appear subsequently. In one series of 53 cases, 41 were detected during the first year of life, while 20 were present at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/42\">",
"     42",
"    </a>",
"    ]. The tumor typically involves the distal extremities, although the head and neck region is affected more frequently in infants than older children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/29,43\">",
"     29,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Molecular biologic and immunohistochemical methods are available to differentiate these tumors from other spindle sarcomas involving children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A characteristic translocation t(12;15)(p13;q25) that results in a fusion gene called ETV6-NTRK3 (also known as Tel-TrkC) has been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although locally infiltrative, these tumors rarely metastasize and have a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. However, the amputation rate exceeds 50 percent, and efforts to successfully salvage limbs by the use of neoadjuvant chemotherapy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/49,51,52\">",
"     49,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Rhabdomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyosarcoma is a highly malignant skeletal muscle neoplasm that arises from embryonal mesenchyme. The primary cutaneous form typically presents as a single firm subcutaneous nodule that adheres to the skin above and tissue underneath [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/34\">",
"     34",
"    </a>",
"    ]. The overlying skin may be erythematous or shiny, occasionally mimicking a deep hemangioma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/53\">",
"     53",
"    </a>",
"    ]. An extremely rare neonatal presentation is alveolar rhabdomyosarcoma, a very aggressive tumor that frequently includes multiple skin and subcutaneous metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neuroblastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroblastoma, the most common malignancy identified at birth, typically presents with an abdominal mass. Metastatic cutaneous lesions are present in approximately one-third of children with congenital neuroblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/34\">",
"     34",
"    </a>",
"    ]. These appear as firm, nontender bluish-red nodules and papules distributed over the entire body. The lesions have a distinctive response to rubbing characterized by central blanching with a surrounding halo of erythema that persists for 30 to 60 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/34,56\">",
"     34,56",
"    </a>",
"    ]. The mechanism is thought to be vasoconstriction induced by catecholamine release [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/57\">",
"     57",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Congenital leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital leukemia is an extremely rare disorder that typically presents at birth with hepatosplenomegaly, petechiae, and ecchymoses. Many affected patients have",
"    <span class=\"nowrap\">",
"     red/brown",
"    </span>",
"    nodules with confluent purpura caused by infiltration of the skin by leukemic cells and known as leukemia cutis (",
"    <a class=\"graphic graphic_picture graphicRef67908 \" href=\"UTD.htm?34/29/35283\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6840/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A variety of cutaneous and subcutaneous nodules may be detected in the newborn. Most are benign and self-limited (eg, cysts), but some may be related to malignancy or a marker for other abnormalities (eg, neural tube defect). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dermoid cysts are small (1 to 4 cm in diameter), usually solitary, slow-growing, asymptomatic, rubbery, nontender masses that appear skin-colored or blue; the skin overlying the cyst appears normal unless a pit or a sinus is present. They are commonly located over the anterior fontanelle, junction of the coronal and sagittal sutures, upper lateral region of the forehead, lateral upper eyelid, and submental region. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dermoid cysts and sinuses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thyroglossal duct cysts are the most common congenital cyst in the neck; they characteristically present as a midline neck mass at the level of the thyrohyoid membrane. Branchial cleft cysts are commonly located anterior to the sternocleidomastoid muscle on the lower third of the lateral neck or at the head of the clavicles. Epidermal cysts result when epidermal cells located within the dermis proliferate and do not communicate with the surface. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Other cysts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Subcutaneous fat necrosis (SFN) is a rare condition that typically affects term or postterm newborns in the first few weeks of life; it usually follows perinatal complications. It is characterized by multiple firm nontender subcutaneous nodules or large plaques over bony prominences (eg, cheeks, buttocks, back, limbs); the overlying skin may be erythematous. SFN may be associated with hypercalcemia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Subcutaneous fat necrosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Benign soft tissue tumors in newborns and infants include infantile hemangiomas, vascular malformations, infantile myofibromatosis, congenital self-healing reticulohistiocytosis, and cutaneous mastocytosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Benign tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignant tumors affecting the skin and soft tissues of newborns and infants include infantile fibrosarcoma, rhabdomyosarcoma, neuroblastoma, and congenital leukemia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Malignant tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/1\">",
"      Drolet BA. Cutaneous signs of neural tube dysraphism. Pediatr Clin North Am 2000; 47:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/2\">",
"      Ackerman LL, Menezes AH. Spinal congenital dermal sinuses: a 30-year experience. Pediatrics 2003; 112:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/3\">",
"      Guggisberg D, Hadj-Rabia S, Viney C, et al. Skin markers of occult spinal dysraphism in children: a review of 54 cases. Arch Dermatol 2004; 140:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/4\">",
"      Douvoyiannis M, Goldman DL, Abbott IR 3rd, Litman N. Posterior fossa dermoid cyst with sinus tract and meningitis in a toddler. Pediatr Neurol 2008; 39:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/5\">",
"      Brownstein MH, Helwig EB. Subcutaneous dermoid cysts. Arch Dermatol 1973; 107:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/6\">",
"      Baldwin HE, Berck CM, Lynfield YL. Subcutaneous nodules of the scalp: preoperative management. J Am Acad Dermatol 1991; 25:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/7\">",
"      Mallory SB. Subcutaneous scalp lesions in children. J Am Acad Dermatol 1993; 28:131.",
"     </a>",
"    </li>",
"    <li>",
"     Cutaneous tumors and tumor syndromes. In: Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of Childhood and Adolescence, 3rd edition, Paller, AS, Mancini, AJ, (Eds), W.B. Elsevier Saunders, Philadelphia 2006. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/9\">",
"      Burden AD, Krafchik BR. Subcutaneous fat necrosis of the newborn: a review of 11 cases. Pediatr Dermatol 1999; 16:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/10\">",
"      Tran JT, Sheth AP. Complications of subcutaneous fat necrosis of the newborn: a case report and review of the literature. Pediatr Dermatol 2003; 20:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/11\">",
"      Hicks MJ, Levy ML, Alexander J, Flaitz CM. Subcutaneous fat necrosis of the newborn and hypercalcemia: case report and review of the literature. Pediatr Dermatol 1993; 10:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/12\">",
"      Mah&eacute; E, Girszyn N, Hadj-Rabia S, et al. Subcutaneous fat necrosis of the newborn: a systematic evaluation of risk factors, clinical manifestations, complications and outcome of 16 children. Br J Dermatol 2007; 156:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/13\">",
"      Oza V, Treat J, Cook N, et al. Subcutaneous fat necrosis as a complication of whole-body cooling for birth asphyxia. Arch Dermatol 2010; 146:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/14\">",
"      Chuang SD, Chiu HC, Chang CC. Subcutaneous fat necrosis of the newborn complicating hypothermic cardiac surgery. Br J Dermatol 1995; 132:805.",
"     </a>",
"    </li>",
"    <li>",
"     Hoath, SB, Narendran, V. The skin. In: Neonatal-Perinatal Medicine, 9th Ed, Fanaroff, AA,  Martin , RJ, Walsh, MC (Eds), Elsevier Mosby, St. Louis 2011. p.1705.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/16\">",
"      Walker WP, Smith RJ, Cohen MB. Fine-needle aspiration biopsy of subcutaneous fat necrosis of the newborn. Diagn Cytopathol 1993; 9:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/17\">",
"      Jardine D, Atherton DJ, Trompeter RS. Sclerema neonatorum and subcutaneous fat necrosis of the newborn in the same infant. Eur J Pediatr 1990; 150:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/18\">",
"      Zeb A, Darmstadt GL. Sclerema neonatorum: a review of nomenclature, clinical presentation, histological features, differential diagnoses and management. J Perinatol 2008; 28:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/19\">",
"      Thomsen RJ. Subcutaneous fat necrosis of the newborn and idiopathic hypercalcemia. Report of a case. Arch Dermatol 1980; 116:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/20\">",
"      Alos N, Eug&egrave;ne D, Fillion M, et al. Pamidronate: Treatment for severe hypercalcemia in neonatal subcutaneous fat necrosis. Horm Res 2006; 65:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/21\">",
"      Lombardi G, Cabano R, Bollani L, et al. Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report. Eur J Pediatr 2009; 168:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/22\">",
"      Karochristou K, Siahanidou T, Kakourou-Tsivitanidou T, et al. Subcutaneous fat necrosis associated with severe hypocalcaemia in a neonate. J Perinatol 2006; 26:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/23\">",
"      Chen TH, Shewmake SW, Hansen DD, Lacey HL. Subcutaneous fat necrosis of the newborn. A case report. Arch Dermatol 1981; 117:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/24\">",
"      Oswalt GC Jr, Montes LF, Cassady G. Subcutaneous fat necrosis of the newborn. J Cutan Pathol 1978; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/25\">",
"      Lewis A, Cowen P, Rodda C, Dyall-Smith D. Subcutaneous fat necrosis of the newborn complicated by hypercalcaemia and thrombocytopenia. Australas J Dermatol 1992; 33:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/26\">",
"      Sharata H, Postellon DC, Hashimoto K. Subcutaneous fat necrosis, hypercalcemia, and prostaglandin E. Pediatr Dermatol 1995; 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/27\">",
"      Wolach B, Raas-Rothschild A, Vogel R, et al. Subcutaneous fat necrosis with thrombocytopenia in a newborn infant. Dermatologica 1990; 181:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/28\">",
"      Caple JI, Reyes S. Subcutaneous fat necrosis of the newborn: a case presentation. J Perinatol 1996; 16:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/29\">",
"      Coffin CM, Dehner LP. Soft tissue tumors in first year of life: a report of 190 cases. Pediatr Pathol 1990; 10:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/30\">",
"      Wiswell TE, Davis J, Cunningham BE, et al. Infantile myofibromatosis: the most common fibrous tumor of infancy. J Pediatr Surg 1988; 23:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/31\">",
"      Coffin CM, Dehner LP. Fibroblastic-myofibroblastic tumors in children and adolescents: a clinicopathologic study of 108 examples in 103 patients. Pediatr Pathol 1991; 11:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/32\">",
"      Chung EB, Enzinger FM. Infantile myofibromatosis. Cancer 1981; 48:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/33\">",
"      Larralde M, Hoffner MV, Boggio P, et al. Infantile myofibromatosis: report of nine patients. Pediatr Dermatol 2010; 27:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/34\">",
"      Wyatt AJ, Hansen RC. Pediatric skin tumors. Pediatr Clin North Am 2000; 47:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/35\">",
"      Briselli MF, Soule EH, Gilchrist GS. Congenital fibromatosis: report of 18 cases of solitary and 4 cases of multiple tumors. Mayo Clin Proc 1980; 55:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/36\">",
"      Ebert CS Jr, Zdanski C, Ardeshirpour F, et al. Recurrent infantile myofibromatosis: a report of conservative management and discussion of treatment strategies. Ear Nose Throat J 2008; 87:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/37\">",
"      Bernstein EF, Resnik KS, Loose JH, et al. Solitary congenital self-healing reticulohistiocytosis. Br J Dermatol 1993; 129:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/38\">",
"      Inuzuka M, Tomita K, Tokura Y, Takigawa M. Congenital self-healing reticulohistiocytosis presenting with hemorrhagic bullae. J Am Acad Dermatol 2003; 48:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/39\">",
"      Kapur P, Erickson C, Rakheja D, et al. Congenital self-healing reticulohistiocytosis (Hashimoto-Pritzker disease): ten-year experience at Dallas Children's Medical Center. J Am Acad Dermatol 2007; 56:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/40\">",
"      Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol 2008; 25:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/41\">",
"      Longaker MA, Frieden IJ, LeBoit PE, Sherertz EF. Congenital \"self-healing\" Langerhans cell histiocytosis: the need for long-term follow-up. J Am Acad Dermatol 1994; 31:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/42\">",
"      Chung EB, Enzinger FM. Infantile fibrosarcoma. Cancer 1976; 38:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/43\">",
"      Blocker S, Koenig J, Ternberg J. Congenital fibrosarcoma. J Pediatr Surg 1987; 22:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/44\">",
"      Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/45\">",
"      Sebire NJ, Ramsay AD, Levitt G, et al. Aberrant immunohistochemical expression in nonrhabdomyosarcoma soft tissue sarcomas of infancy: retrospective review of clinical material. Pediatr Dev Pathol 2002; 5:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/46\">",
"      Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: congenital (infantile) fibrosarcoma and mesoblastic nephroma. Cancer Genet Cytogenet 2002; 132:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/47\">",
"      Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000; 24:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/48\">",
"      Ferguson WS. Advances in the adjuvant treatment of infantile fibrosarcoma. Expert Rev Anticancer Ther 2003; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/49\">",
"      Loh ML, Ahn P, Perez-Atayde AR, et al. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children's Hospital, Boston. J Pediatr Hematol Oncol 2002; 24:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/50\">",
"      Cecchetto G, Carli M, Alaggio R, et al. Fibrosarcoma in pediatric patients: results of the Italian Cooperative Group studies (1979-1995). J Surg Oncol 2001; 78:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/51\">",
"      McCahon E, Sorensen PH, Davis JH, et al. Non-resectable congenital tumors with the ETV6-NTRK3 gene fusion are highly responsive to chemotherapy. Med Pediatr Oncol 2003; 40:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/52\">",
"      Russell H, Hicks MJ, Bertuch AA, Chintagumpala M. Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer 2009; 53:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/53\">",
"      Megarbane H, Doz F, Manach Y, et al. Neonatal rhabdomyosarcoma misdiagnosed as a congenital hemangioma. Pediatr Dermatol 2011; 28:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/54\">",
"      Rodriguez-Galindo C, Hill DA, Onyekwere O, et al. Neonatal alveolar rhabdomyosarcoma with skin and brain metastases. Cancer 2001; 92:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/55\">",
"      Grundy R, Anderson J, Gaze M, et al. Congenital alveolar rhabdomyosarcoma: clinical and molecular distinction from alveolar rhabdomyosarcoma in older children. Cancer 2001; 91:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/56\">",
"      Lucky AW, McGuire J, Komp DM. Infantile neuroblastoma presenting with cutaneous blanching nodules. J Am Acad Dermatol 1982; 6:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/57\">",
"      Schneider KM, Becker JM, Krasna IH. Neonatal neuroblastoma. Pediatrics 1965; 36:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/58\">",
"      Francis JS, Sybert VP, Benjamin DR. Congenital monocytic leukemia: report of a case with cutaneous involvement, and review of the literature. Pediatr Dermatol 1989; 6:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6840/abstract/59\">",
"      Dinulos JG, Hawkins DS, Clark BS, Francis JS. Spontaneous remission of congenital leukemia. J Pediatr 1997; 131:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5788 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-7F6A7747C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6840=[""].join("\n");
var outline_f6_43_6840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CYSTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dermoid cysts and sinuses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Other cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SUBCUTANEOUS FAT NECROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benign tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Infantile myofibromatosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Congenital self-healing reticulohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Malignant tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Infantile fibrosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Congenital leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5788\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5788|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/20/20803\" title=\"picture 1\">",
"      Dermoid cyst inflamed",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/51/32564\" title=\"picture 2\">",
"      Dermoid cyst forehead",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/48/27392\" title=\"picture 3\">",
"      Branchial cleft cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/56/38785\" title=\"picture 4A\">",
"      Infantile myofibroma head",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/29/25042\" title=\"picture 4B\">",
"      Infantile myofibroma back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/49/15121\" title=\"picture 4C\">",
"      Infantile myofibroma trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/28/30146\" title=\"picture 5\">",
"      Congenital histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/39/17010\" title=\"picture 6\">",
"      Congenital histiocytosis foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/50/30497\" title=\"picture 7A\">",
"      Mastocytoma infant hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/20/44354\" title=\"picture 7B\">",
"      Mastocytoma extremity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/29/35283\" title=\"picture 8\">",
"      Congenital leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5788|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/7/1148\" title=\"table 1\">",
"      SCN versus SN",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/13/22745?source=related_link\">",
"      Benign skin and scalp lesions in the newborn and young infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21338?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44665?source=related_link\">",
"      Epidemiology; pathogenesis; clinical features; and complications of infantile hemangiomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/26999?source=related_link\">",
"      Neonatal hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=related_link\">",
"      Thyroglossal duct cysts and ectopic thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30038?source=related_link\">",
"      Vascular lesions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6841="Exercise-based therapy for low back pain";
var content_f6_43_6841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise-based therapy for low back pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Gwendolyn Sowa, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Anthony Delitto, PhD, PT, FAPTA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6841/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/43/6841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low back pain (LBP) is the most common musculoskeletal problem worldwide, with up to 85 percent of all people experiencing LBP during their lifetimes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/1\">",
"     1",
"    </a>",
"    ]. LBP has a substantial impact on lifestyle, quality of life, and work-related disability. The total costs of LBP in the United States exceed $100 billion per year [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/2\">",
"     2",
"    </a>",
"    ]. Although more than half of patients with LBP present to primary care clinicians, it is frequently managed by a variety of providers, including orthopedists, physiatrists, neurosurgeons, physical therapists, chiropractors, neurologists, rheumatologists, and emergency physicians, all of whom may be involved in referring patients for rehabilitation of the low back [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise-based therapy is an important component of LBP treatment. This topic will discuss exercise therapy as a treatment for acute, subacute, and chronic LBP. Other specific treatment topics for LBP are discussed elsewhere:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link\">",
"       \"Treatment of acute low back pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"       \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"       \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"       \"Subacute and chronic low back pain: Surgical treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=see_link\">",
"       \"Spinal manipulation in the treatment of musculoskeletal pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8169?source=see_link\">",
"       \"Musculoskeletal injury in the young athlete: Overview of rehabilitation for nonoperative injuries\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link\">",
"       \"Occupational low back pain: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological studies suggest that the most serious spine pathology occurs in patients with the highest and lowest degrees of physical activity, while moderate physical loading of the spine has a protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/4\">",
"     4",
"    </a>",
"    ]. Dynamic loading of the spine during exercise therapy facilitates the diffusion of nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/5\">",
"     5",
"    </a>",
"    ], has anabolic effects on intervertebral disc matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/6\">",
"     6",
"    </a>",
"    ], and slows matrix degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXERCISE FOR ACUTE LBP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some studies do show modest efficacy of exercise therapy in selected cases of acute LBP (less than four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], systematic reviews have not clearly demonstrated a treatment benefit of generalized exercise therapy compared to other conservative treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. As an example, in one systematic review of 11 randomized trials of exercise in patients with acute LBP, exercise therapy was not more effective than no treatment or other conservative treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/11\">",
"     11",
"    </a>",
"    ], which included",
"    <span class=\"nowrap\">",
"     NSAIDs/other",
"    </span>",
"    analgesics, patient education programs,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advice to stay active.",
"   </p>",
"   <p>",
"    Exercise regimens vary tremendously between studies, but exercises in acute LBP generally consist of",
"    <span class=\"nowrap\">",
"     flexibility/stretching",
"    </span>",
"    programs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    directional preference (ie, eliciting an immediate, lasting improvement in pain through repeated lumber movements) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/12\">",
"     12",
"    </a>",
"    ]. When directional preference precedes the prescription of exercises, clinical outcomes (pain relief and ability to return to work) may be better than when non-individualized (or 'one size fits all') exercise regimens are prescribed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/8,9,12,13\">",
"     8,9,12,13",
"    </a>",
"    ]. In particular, exercise regimens matched to the patient's source of pain or directed at specific biomechanical impairments are likely to yield greater pain relief. Further trials are needed to assess the benefits of individualized exercise therapy for acute LBP.",
"   </p>",
"   <p>",
"    In general, advice to stay active is better than bed rest for long-term improvement of function in acute LBP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/14\">",
"     14",
"    </a>",
"    ]. In a systematic review, which included two moderate quality randomized trials of patients with acute LBP, patients who were advised to stay active had slightly less pain and slightly improved functional recovery compared to patients advised to rest in bed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/15\">",
"     15",
"    </a>",
"    ]. We recommend that patients with acute LBP remain active and avoid bed rest, which is consistent with many international guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/16\">",
"     16",
"    </a>",
"    ]. A general exercise prescription for LBP is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef50570 \" href=\"UTD.htm?37/1/37918\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXERCISE FOR SUBACUTE AND CHRONIC LBP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the limited evidence of benefit from exercise for acute LBP, exercise therapy has been shown to have modest benefits in patients with subacute (4 to 12 weeks) and chronic LBP (&gt;12 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/17\">",
"     17",
"    </a>",
"    ]. Exercise therapy improves short-term pain relief and function in patients with chronic LBP. In addition, the improvements associated with exercise therapy may be long lasting (&ge;1-3 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both subacute and chronic LBP, exercise therapy is particularly beneficial when the exercise approach includes aerobic activity and is accompanied by biopsychosocial based approaches that include cognitive behavioral strategies facilitating a graded exercise regimen (ie, increasing exercise activity in small steps) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/14,23-25\">",
"     14,23-25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Multidisciplinary rehabilitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Exercise therapy, provided as a directly supervised program in healthcare settings or formal home exercise regimens, has been evaluated in numerous randomized trials. A systematic review of 43 trials found exercise therapy for patients with chronic LBP to be slightly superior to no treatment for pain relief (weighted mean improvement 10.2 points [on a 100 point scale] 95% CI, 1.3-19.1) and functional outcomes (3.0 points, 95% CI 0.5-6.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/17\">",
"     17",
"    </a>",
"    ]. There was also some evidence for the effectiveness of a graded activity exercise program in patients with subacute LBP. Limitations in this systematic review included use of lower quality trials and heterogeneous outcome measures.",
"   </p>",
"   <p>",
"    In addition, a meta-regression analysis found the best outcomes for exercise therapy incorporated all of the following elements [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Individualized regimens",
"     </li>",
"     <li>",
"      Supervision",
"     </li>",
"     <li>",
"      Stretching",
"     </li>",
"     <li>",
"      Strengthening",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared to no treatment, an exercise therapy model that included all of these features, was estimated to improve pain scores by 18 points on a 100 point scale (95% CI, 11-25 points) and function by 6 points (95% CI, 0-10 points). No trials of such an 'ideal' exercise intervention are currently available, although an enormous variety of exercise programs with these individual elements are widely practiced.",
"   </p>",
"   <p>",
"    A major limitation in systematic reviews of exercise therapy for LBP is the inability to directly compare the innumerable forms of activities that can be classified as exercise. Unlike traditional exercise physiology approaches to exercise where increased muscle capacity (either force capability or endurance) is the target, exercise therapy today can take on a much broader conceptual foundation, as evidenced by the variety of exercise programs described below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific exercise programs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Timing and dosage of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the benefits of exercise are not clear in patients with acute LBP, exercise therapy should be delayed in those with very severe pain during the first few weeks and should focus on those who are not improving with time.",
"   </p>",
"   <p>",
"    In the absence of red flags, patients with subacute or chronic LBP should be encouraged to begin an exercise program (",
"    <a class=\"graphic graphic_table graphicRef68550 \" href=\"UTD.htm?25/54/26475\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link&amp;anchor=H20#H20\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\", section on 'Indications for referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing aerobic exercise should follow established guidelines, including a gradual increase in the frequency (to 3 to 5 days per week) and",
"    <span class=\"nowrap\">",
"     intensity/duration",
"    </span>",
"    (a total of 150 minutes of moderate intensity at &gt;55 percent of predicted maximal heart rate) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/26\">",
"     26",
"    </a>",
"    ]. The optimal dosage of other modes of exercise (eg, strengthening, core stability, directional preference) is not known and remains an area that needs further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specific exercise programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different types of exercises are commonly used in patients with subacute or chronic LBP. For most patients with LBP, a specific etiology cannot be established with certainty. For patients with nonspecific LBP, exercise programs include combinations of core strengthening (predominantly abdominal and trunk extensor),",
"    <span class=\"nowrap\">",
"     flexion/extension",
"    </span>",
"    movements, directional preference, mind-body exercises, general physical fitness, aerobic exercise, and functional restoration programs.",
"   </p>",
"   <p>",
"    In evaluating the efficacy of specific exercise programs, inadequate definitions of exercise regimens become problematic when studies are pooled, such as in systematic reviews. Consequently, few systematic reviews are able to adequately assess different types of exercise strategies. Despite these limitations, most studies show that exercise is safe, readily available, and improves both back pain and function.",
"   </p>",
"   <p>",
"    In general, exercise therapies for LBP include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"Core strengthening\" or \"segmental strengthening\" (eg, general strengthening and motor control of key trunk muscles involved in spinal stability). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Core strengthening'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Directional preference includes end-range",
"      <span class=\"nowrap\">",
"       flexion/extension",
"      </span>",
"      stretches with repeated movements that are designed to improve pain symptoms. One application of this method is commonly referred to as the \"McKenzie method\" and is likely to be most effective when matched to presentation of the patient, based on centralization of the patient's symptoms. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'McKenzie method'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Aerobic exercises and functional restoration activities that are commonly designed to motivate the patient or simply increase baseline physical activity levels. Mechanisms of improvement may include increased endurance of postural muscles, improved blood flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Core strengthening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core refers to the abdominal, paraspinal, gluteal, diaphragmatic, pelvic floor, and hip girdle musculature. Exercise programs that emphasize core strengthening aim to train these muscles in a coordinated fashion to facilitate lumbar stability. It should be emphasized that individual muscle strengthening, as accomplished through traditional isolated training, is not the primary goal of core strengthening. Instead, it is teaching the patient to train muscles in an integrated manner to protect from abnormal or traumatic forces.",
"   </p>",
"   <p>",
"    The results of core strengthening interventions are equivocal. Adding generic core strengthening programs to existing treatment regimens does not appear to influence long-term outcome, nor does it appear to reduce recurrences [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. However, applying core exercises to specific populations may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/29\">",
"     29",
"    </a>",
"    ]. Though there are some randomized trials that have demonstrated effectiveness of core strengthening approaches, more research still needs to be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     McKenzie method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The McKenzie method for treatment of LBP is based on directional preference in which patients are taught to perform exercises that focus low back",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiating pain toward the spinal midline, using repeated movements or sustained postures. These techniques primarily rely on patient-generated forces and emphasize self-care.",
"   </p>",
"   <p>",
"    One systematic review found little to no difference between the McKenzie method and either flexion or strengthening exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/30\">",
"     30",
"    </a>",
"    ]. However, this review had several limitations, particularly the inclusion of studies whose methods were inconsistent with a central tenant of the McKenzie method (determining a directional preference and matching an exercise regimen to that preference), as well as non-inclusion of studies that were consistent with McKenzie methods. There was also significant heterogeneity between studies that limited pooling of data in this review.",
"   </p>",
"   <p>",
"    There are some data to show that the McKenzie method is effective in patients with subacute and chronic low back pain. In one multi-center randomized trial, matching a patient's exercise patterns to his or her direction of least discomfort resulted in rapidly decreased pain and medication use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Alexander technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Alexander technique involves individualized, hands-on instruction to improve balance, posture, and coordination, as well as recognition of harmful habits of muscle use in order to avoid painful movements. A randomized trial of 479 patients with chronic or recurrent LBP found 24 sessions of the Alexander technique moderately effective at 12 months, although six sessions were not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the combination of six sessions of the Alexander technique with a doctor's prescription for home based exercise also resulted in moderate benefit in terms of pain relief and reduction in disability, and was also more cost-effective compared to usual care or massage therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mind body exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches such as yoga and pilates, which address strength, flexibility, and balance, as well as relaxation techniques, incorporate many of the goals of a LBP rehabilitation approach. Yoga incorporates specific body positioning, breathing techniques, and mental focus that may alleviate LBP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281041167\">",
"    <span class=\"h4\">",
"     Yoga",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most randomized trials have found that yoga is superior to self-care, but similarly effective to performing exercises involving the lower back [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In a randomized trial of 228 adults with chronic LBP, those assigned to yoga reported improved pain and function at 12 weeks compared to self-care and similar improvements compared to stretching exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/35\">",
"     35",
"    </a>",
"    ]. In a randomized trial of 313 adults with chronic or recurrent LBP, those assigned to 12 weeks of yoga reported better back function at 3, 6, and 12 months compared with usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/34\">",
"     34",
"    </a>",
"    ]. However, more patients in the yoga arm reported adverse events than the usual care arm, mostly due to increased back pain (8 versus 1 percent).",
"   </p>",
"   <p>",
"    Specific schools of yoga may be particularly beneficial for chronic LBP, with certain styles emphasizing different postures and techniques. A randomized trial of 101 patients with chronic LBP found viniyoga (12 weekly 75 minute sessions) improved functional status and symptoms at 12 weeks compared to two other interventions: a back exercise class or a self-care book. At 26 weeks, outcomes for yoga were equivalent to the exercise class but remained superior to the self-care book [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/32\">",
"     32",
"    </a>",
"    ]. Yoga was also associated with decreased medication use compared to the exercise class or self-care book. The viniyoga program combined breathing techniques, simple yoga postures, and deep relaxation. Small trials comparing Iyengar yoga (a style of Hatha yoga that uses physical props) to exercise instruction or standard exercise were inconclusive, though suggested a trend of improvement for the yoga participants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. A larger trial (n = 90) demonstrated that Iyengar yoga participants had an improvement in functional ability and less pain medication usage at 24 weeks compared to patients receiving standard medical care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/33\">",
"     33",
"    </a>",
"    ]. A major limitation of this study was a high dropout rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281041174\">",
"    <span class=\"h4\">",
"     Pilates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to traditional core stabilization programs, pilates focuses on stabilizing the core prior to challenging movements. It has been shown to be superior to usual care in reducing disability in patients with chronic LBP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. As an example, in one randomized trial of pilates versus usual care in 39 patients with chronic LBP, patients randomly assigned to pilates reported less disability and improved pain compared to the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1281041188\">",
"    <span class=\"h4\">",
"     Tai chi",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tai chi is a Chinese martial art that involves slow movements, breathing exercises, and meditation. In a randomized trial of 160 adults with nonspecific LBP, those assigned to a tai chi program reported improved pain and disability after 10 weeks of treatment, compared to usual care [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/40\">",
"     40",
"    </a>",
"    ]. Further trials are needed to determine long-term efficacy of tai chi in the treatment of LBP and how it compares to other active treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Home-based programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials have found home exercise programs to be effective in treating LBP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/41-45\">",
"     41-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized, multicenter trial of patients with nonspecific chronic LBP, 201 patients were randomly assigned to home-based trunk muscle",
"    <span class=\"nowrap\">",
"     strengthening/stretching",
"    </span>",
"    exercises or nonsteroidal antiinflammatory drugs (NSAIDs) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/45\">",
"     45",
"    </a>",
"    ]. Home exercise therapy consisted of ten repetitions twice daily of both strengthening and stretching exercises. Both exercise and NSAIDs arms were followed once or twice weekly in clinic for eight weeks to ensure patients were correctly adhering to treatment. After 12 months of follow-up, patients receiving exercise therapy had significantly greater improvement in disability scores than those randomly assigned to NSAIDs.",
"   </p>",
"   <p>",
"    In another randomized trial of patients with chronic LBP, 117 patients were randomly assigned to a home-based rehabilitation program or standard outpatient exercise therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/44\">",
"     44",
"    </a>",
"    ]. Patients received four weekly sessions and were followed over a year. Patients receiving home-based rehabilitation did significantly better than patients receiving standard outpatient exercise therapy, although both groups showed improvement in pain scores, flexibility, muscle endurance, and function. In addition, at one year, patients were more compliant with the home-based program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aquatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systemic review of seven controlled trials found that therapeutic aquatic exercise was beneficial, but no better than other interventions for chronic LBP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/46\">",
"     46",
"    </a>",
"    ]. However, methodological quality was considered low for all of the trials, and there was heterogeneity in patient symptoms and outcome measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Back schools",
"    </span>",
"    &nbsp;&mdash;&nbsp;Back schools typically exist outside of the traditional health care system and are managed by large companies or occupational health centers. Generally, lessons are provided to groups of patients and supervised by a physical therapist or other therapist trained in back rehabilitation. There is moderate evidence that back schools improve short-term recovery and return to work. Back schools are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link&amp;anchor=H10#H10\">",
"     \"Occupational low back pain: Treatment\", section on 'Back schools and other educational interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Functional restoration programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional restoration, also known as work hardening, involves simulated or actual onsite work testing in a supervised environment to improve strength, endurance, flexibility, and fitness for injured workers. This often involves a multidisciplinary component, including physical and occupational therapy. Functional restoration differs from back school in the emphasis on individualized exercise therapy compared to group educational training for back school programs. Functional restoration programs are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link&amp;anchor=H11#H11\">",
"     \"Occupational low back pain: Treatment\", section on 'Functional restoration or work hardening programs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Compliance with exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any other prescription, response to the treatment requires patient compliance. Multiple barriers exist, and a clinician must address each patient's individual barriers in order to maximize compliance and efficacy. Reasons for non-compliance include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Beliefs about their illness",
"     </li>",
"     <li>",
"      Beliefs about adherence (eg, outcome expectations with exercises)",
"     </li>",
"     <li>",
"      Lack of time",
"     </li>",
"     <li>",
"      Tiredness",
"     </li>",
"     <li>",
"      Comorbidities",
"     </li>",
"     <li>",
"      Lack of social support",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Psychosocial barriers to exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encouragement of prompt return to normal activities is one of the most common recommendations for people who experience an episode of LBP, having been cited in virtually every guideline and systematic review since the mid-1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, patients often avoid physical activity for fear of making their spine \"pathology\" worse, which can be an obstacle to recovery. In fact, overt avoidance of activity due to fear, commonly termed fear avoidance, is a well-founded biopsychosocial factor that, when compared to physical factors, better accounts for poor long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fear avoidance behavior can be exacerbated by the clinician's use of diagnoses that are not only questionable with regard to being causative to the problem (eg, degenerative disc disease) but also serve to \"medicalize\" the problem and discourage attempts at activating the patient, thus leading to an additional barrier for recovery. In fact, intervertebral disc degeneration along with a myriad of other imaging findings are ubiquitous among aging patients and highly prevalent in people without symptoms. Thus, the clinician should advise the patient that while anatomical changes represent a normal result of aging to some extent, they do not predict lifelong pain or disability, nor should they deter the person from initiating an exercise program and re-engaging in normal activities. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Disease specific approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Coexistence of more severe psychosocial and psychological problems (eg, depression) can contribute to non-recovery and may require further diagnostic workup and more specific interventions in order to optimize the chances for recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/23\">",
"     23",
"    </a>",
"    ]. Even in the most severe cases where psychosocial influences appear to overshadow most physical signs related to LBP, most recommendations suggest an approach that takes into account both physical and psychosocial factors, such as in multidisciplinary programs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Multidisciplinary rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multidisciplinary, or interdisciplinary, therapy combines physical, vocational, and behavioral components provided by multiple health care professionals. Intensity and content of interdisciplinary therapy vary widely. These programs combine graded exercise therapy with a psychosocial approach, generally involving a psychologist. Multidisciplinary therapy can be similar to functional restoration programs but emphasize multiple providers and behavioral interventions.",
"   </p>",
"   <p>",
"    A systematic review found multidisciplinary rehabilitation with a workplace visit more effective than usual care for subacute LBP, alleviating subjective disability, and resulting in quicker return to work [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/23\">",
"     23",
"    </a>",
"    ]. However, this study included only two trials, each with methodological shortcomings. Another systematic review found intensive, daily multidisciplinary rehabilitation was moderately superior to non-multidisciplinary rehabilitation or usual care for short- and long-term functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/51\">",
"     51",
"    </a>",
"    ]. Less intensive multidisciplinary rehabilitation was no better than usual care.",
"   </p>",
"   <p>",
"    Patients are more likely to benefit from multidisciplinary rehabilitation and functional restoration if they are highly motivated, as the most effective regimens are intensive. The high cost of the more intensive programs limit their applicability; they may be most appropriate for patients who do not respond to single interventions, or as an alternative to surgery. We advise referring physicians be familiar with outcomes for specific programs, given the cost and heterogeneity of quality among programs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multidisciplinary programs may not be available in many communities. They are usually practiced in pain clinics or rehabilitation centers. It is uncertain whether providing the components of multidisciplinary rehabilitation outside of a formal program is as effective as a coordinated program. If not available, the primary care clinician may be left the task of coordinating a collaborative arrangement between the various specialists, for which the logistics are burdensome. Primary care clinicians may need to develop and coordinate an individualized care program, involving a physical or occupational therapist, a behavioral psychologist experienced in patients with musculoskeletal symptoms, and a rehabilitation or occupational physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DISEASE SPECIFIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;An etiologic diagnosis is not established for most patients with LBP. Even for patients with a specific condition that has been associated with LBP, correlation between anatomic changes in the spine and patient symptoms is weak [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. For example, anatomic lumbar spinal stenosis is noted on imaging studies in many asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, most episodes of back pain are self-limited and resolve without specific therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=see_link\">",
"     \"Diagnostic testing for low back pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with symptoms that are attributed to a specific spinal disease, there is a lack of randomized trials to guide choice of rehabilitation therapy, and it remains unclear which types of rehabilitation are best suited for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Lumbar spinal stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar spinal stenosis (LSS) refers to an anatomic condition that includes narrowing of the intraspinal (central) canal, lateral recess,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neural foramen. Neurogenic claudication is the hallmark symptom of symptomatic lumbar spinal stenosis. Non-surgical treatment, including exercise therapy, is the mainstay of conservative management for LSS. However, there is limited evidence supporting exercise therapy in any form for the treatment of LSS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=see_link\">",
"     \"Lumbar spinal stenosis: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lumbosacral radiculopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common etiology of lumbosacral radiculopathy (sometimes referred to as sciatica) is nerve root compression caused by a disc herniation or spondylosis (ie, lumbar spinal stenosis due to degenerative arthritis affecting the spine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exercise and manual therapy are often tried for patients with persistent symptoms that are mild or moderate in nature. There is little evidence that such treatments are effective for acute radiculopathy. Given the generally favorable natural history of acute lumbosacral radiculopathy, it is reasonable to delay such interventions until symptoms have persisted for two to three weeks depending on the severity of symptoms. In a randomized trial in patients with severe radicular pain below the knee for two weeks to one year, patients assigned to active treatment with symptom-guided exercises (including McKenzie method, stabilizing, directional, and postural exercises) showed more clinically-important improvement in functional status and pain compared to patients assigned to a program with sham exercises; all patients received the same educational materials and advice to remain active [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=see_link\">",
"     \"Acute lumbosacral radiculopathy: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Following lumbar disc surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that patients need to have their activities restricted after first-time lumbar disc surgery. In a systematic review of 13 randomized trials, there was strong evidence of efficacy for intensive exercise programs starting four to six weeks postoperatively and no evidence that they increase the reoperation rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/59\">",
"     59",
"    </a>",
"    ]. It is unclear what the exact content of postsurgery rehabilitation should be. Moreover, there are no studies that investigated whether active rehabilitation programs should start immediately postsurgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Spondylolysis and spondylolisthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondylolysis refers to a defect in the pars interarticularis (a bone connecting one facet joint to another). Spondylolysis is often asymptomatic and detected incidentally as a radiologic finding, although it may also be associated with low back pain. Isthmic spondylolisthesis refers to a condition in which lytic spondylolysis results in anterior subluxation of the affected vertebral body.",
"   </p>",
"   <p>",
"    A systematic review of two randomized trials found that a specific exercise intervention, alone or in combination with other treatments, improved pain symptoms in patients with spondylolysis or spondylolisthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/60\">",
"     60",
"    </a>",
"    ]. However, there was significant heterogeneity between the two studies and both were rated as weak evidence. No specific conclusions can be made on the basis of this review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=see_link\">",
"     \"Subacute and chronic low back pain: Surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to refer a patient to a physical therapist, physiatrist, or other rehabilitation specialist depends upon the presentation of the individual patient and the experience of the clinician in providing exercise therapy. It is important that the treating clinician encourages early activation of the patient, incorporates aerobic and general fitness, and facilitates early return to normal activities which includes any occupational duties.",
"   </p>",
"   <p>",
"    All patients need some level of oversight when performing an exercise regimen with which they have no prior experience. As discussed above, the most appropriate therapy is individualized to the patient's symptoms and response to specific exercises. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific exercise programs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A physical therapy referral is an appropriate option for primary care clinicians who lack experience in supervising exercise therapy for low back pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVENTION OF LBP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The European Guidelines for Prevention in Low Back Pain suggest that primary prevention of LBP is feasible and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/61\">",
"     61",
"    </a>",
"    ]. However, primary prevention of LBP presents a formidable challenge due to the inability to predict a person's likelihood of developing debilitating LBP. Thus, many have questioned the current utility of LBP prevention methods.",
"   </p>",
"   <p>",
"    Many believe exercise therapy might have a role in secondary prevention, particularly for those predisposed to having recurrent LBP. In a systematic review that included nine observational studies, post-treatment exercises were more effective than no intervention for reducing the rate of LBP recurrence at one year (RR 0.50, 95% CI 0.34-0.73) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6841/abstract/62\">",
"     62",
"    </a>",
"    ]. The most promising approaches seem to involve back flexibility and strengthening exercises.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise therapy is a common treatment modality for low back pain (LBP), especially for those with subacute (4 to 12 weeks) and chronic LBP (&gt;12 weeks). The exercise regimen should be tailored and clearly specified, based on the presentation of the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although non-individualized back exercise regimens have not been clearly shown to improve outcomes in patients with acute LBP (&lt;4 weeks), they do reduce pain and improve function in patients with subacute (4 to 12 weeks) and chronic LBP (&gt;12 weeks). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exercise for acute LBP'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Exercise for subacute and chronic LBP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute LBP, we recommend remaining active rather than bed rest (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Exercise for acute LBP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with nonspecific subacute and chronic LBP, we suggest exercise therapy rather than no therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Direct supervision, individualized therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      formal home-based programs are preferred. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Exercise for subacute and chronic LBP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent LBP despite exercise therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      those with a psychosocial component, we suggest more intense rehabilitation approaches, such as multidisciplinary interventions, which include physical, vocational, and behavioral therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In work-related environments, functional restoration programs and back schools may offer some benefit. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Multidisciplinary rehabilitation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=see_link\">",
"       \"Occupational low back pain: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/1\">",
"      Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003; 81:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/2\">",
"      Katz JN. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am 2006; 88 Suppl 2:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/3\">",
"      Cypress BK. Characteristics of physician visits for back symptoms: a national perspective. Am J Public Health 1983; 73:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/4\">",
"      Videman T, Nurminen M, Troup JD. 1990 Volvo Award in clinical sciences. Lumbar spinal pathology in cadaveric material in relation to history of back pain, occupation, and physical loading. Spine (Phila Pa 1976) 1990; 15:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/5\">",
"      Urban JP, Smith S, Fairbank JC. Nutrition of the intervertebral disc. Spine (Phila Pa 1976) 2004; 29:2700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/6\">",
"      Walsh AJ, Lotz JC. Biological response of the intervertebral disc to dynamic loading. J Biomech 2004; 37:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/7\">",
"      Handa T, Ishihara H, Ohshima H, et al. Effects of hydrostatic pressure on matrix synthesis and matrix metalloproteinase production in the human lumbar intervertebral disc. Spine (Phila Pa 1976) 1997; 22:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/8\">",
"      Brennan GP, Fritz JM, Hunter SJ, et al. Identifying subgroups of patients with acute/subacute \"nonspecific\" low back pain: results of a randomized clinical trial. Spine (Phila Pa 1976) 2006; 31:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/9\">",
"      Fritz JM, Delitto A, Erhard RE. Comparison of classification-based physical therapy with therapy based on clinical practice guidelines for patients with acute low back pain: a randomized clinical trial. Spine (Phila Pa 1976) 2003; 28:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/10\">",
"      Faas A. Exercises: which ones are worth trying, for which patients, and when? Spine (Phila Pa 1976) 1996; 21:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/11\">",
"      van Tulder MW, Malmivaara A, Esmail R, Koes BW. Exercise therapy for low back pain. Cochrane Database Syst Rev 2000; :CD000335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/12\">",
"      Machado LA, Maher CG, Herbert RD, et al. The effectiveness of the McKenzie method in addition to first-line care for acute low back pain: a randomized controlled trial. BMC Med 2010; 8:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/13\">",
"      Long A, Donelson R, Fung T. Does it matter which exercise? A randomized control trial of exercise for low back pain. Spine (Phila Pa 1976) 2004; 29:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/14\">",
"      van Tulder MW, Koes B, Malmivaara A. Outcome of non-invasive treatment modalities on back pain: an evidence-based review. Eur Spine J 2006; 15 Suppl 1:S64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/15\">",
"      Dahm KT, Brurberg KG, Jamtvedt G, Hagen KB. Advice to rest in bed versus advice to stay active for acute low-back pain and sciatica. Cochrane Database Syst Rev 2010; :CD007612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/16\">",
"      Bouwmeester W, van Enst A, van Tulder M. Quality of low back pain guidelines improved. Spine (Phila Pa 1976) 2009; 34:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/17\">",
"      Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev 2005; :CD000335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/18\">",
"      Rainville J, Hartigan C, Martinez E, et al. Exercise as a treatment for chronic low back pain. Spine J 2004; 4:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/19\">",
"      Cohen I, Rainville J. Aggressive exercise as treatment for chronic low back pain. Sports Med 2002; 32:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/20\">",
"      Liddle SD, Baxter GD, Gracey JH. Exercise and chronic low back pain: what works? Pain 2004; 107:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/21\">",
"      Maher CG. Effective physical treatment for chronic low back pain. Orthop Clin North Am 2004; 35:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/22\">",
"      van Middelkoop M, Rubinstein SM, Verhagen AP, et al. Exercise therapy for chronic nonspecific low-back pain. Best Pract Res Clin Rheumatol 2010; 24:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/23\">",
"      Karjalainen K, Malmivaara A, van Tulder M, et al. Multidisciplinary biopsychosocial rehabilitation for subacute low back pain among working age adults. Cochrane Database Syst Rev 2003; :CD002193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/24\">",
"      Hayden JA, van Tulder MW, Tomlinson G. Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain. Ann Intern Med 2005; 142:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/25\">",
"      van Tulder MW, Ostelo RW, Vlaeyen JW, et al. Behavioural treatment for chronic low back pain. Cochrane Database Syst Rev 2000; :CD002014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/26\">",
"      Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/27\">",
"      Cairns MC, Foster NE, Wright C. Randomized controlled trial of specific spinal stabilization exercises and conventional physiotherapy for recurrent low back pain. Spine (Phila Pa 1976) 2006; 31:E670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/28\">",
"      Koumantakis GA, Watson PJ, Oldham JA. Trunk muscle stabilization training plus general exercise versus general exercise only: randomized controlled trial of patients with recurrent low back pain. Phys Ther 2005; 85:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/29\">",
"      O'Sullivan PB, Phyty GD, Twomey LT, Allison GT. Evaluation of specific stabilizing exercise in the treatment of chronic low back pain with radiologic diagnosis of spondylolysis or spondylolisthesis. Spine (Phila Pa 1976) 1997; 22:2959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/30\">",
"      Machado LA, de Souza Mv, Ferreira PH, Ferreira ML. The McKenzie method for low back pain: a systematic review of the literature with a meta-analysis approach. Spine (Phila Pa 1976) 2006; 31:E254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/31\">",
"      Little P, Lewith G, Webley F, et al. Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain. BMJ 2008; 337:a884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/32\">",
"      Sherman KJ, Cherkin DC, Erro J, et al. Comparing yoga, exercise, and a self-care book for chronic low back pain: a randomized, controlled trial. Ann Intern Med 2005; 143:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/33\">",
"      Williams K, Abildso C, Steinberg L, et al. Evaluation of the effectiveness and efficacy of Iyengar yoga therapy on chronic low back pain. Spine (Phila Pa 1976) 2009; 34:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/34\">",
"      Tilbrook HE, Cox H, Hewitt CE, et al. Yoga for chronic low back pain: a randomized trial. Ann Intern Med 2011; 155:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/35\">",
"      Sherman KJ, Cherkin DC, Wellman RD, et al. A randomized trial comparing yoga, stretching, and a self-care book for chronic low back pain. Arch Intern Med 2011; 171:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/36\">",
"      Galantino ML, Bzdewka TM, Eissler-Russo JL, et al. The impact of modified Hatha yoga on chronic low back pain: a pilot study. Altern Ther Health Med 2004; 10:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/37\">",
"      Williams KA, Petronis J, Smith D, et al. Effect of Iyengar yoga therapy for chronic low back pain. Pain 2005; 115:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/38\">",
"      Rydeard R, Leger A, Smith D. Pilates-based therapeutic exercise: effect on subjects with nonspecific chronic low back pain and functional disability: a randomized controlled trial. J Orthop Sports Phys Ther 2006; 36:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/39\">",
"      Donzelli S, Di Domenica E, Cova AM, et al. Two different techniques in the rehabilitation treatment of low back pain: a randomized controlled trial. Eura Medicophys 2006; 42:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/40\">",
"      Hall AM, Maher CG, Lam P, et al. Tai chi exercise for treatment of pain and disability in people with persistent low back pain: a randomized controlled trial. Arthritis Care Res (Hoboken) 2011; 63:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/41\">",
"      Bentsen H, Lindg&auml;rde F, Manthorpe R. The effect of dynamic strength back exercise and/or a home training program in 57-year-old women with chronic low back pain. Results of a prospective randomized study with a 3-year follow-up period. Spine (Phila Pa 1976) 1997; 22:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/42\">",
"      Kuukkanen T, M&auml;lki&auml; E, Kautiainen H, Pohjolainen T. Effectiveness of a home exercise programme in low back pain: a randomized five-year follow-up study. Physiother Res Int 2007; 12:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/43\">",
"      H&auml;kkinen A, Ylinen J, Kautiainen H, et al. Effects of home strength training and stretching versus stretching alone after lumbar disk surgery: a randomized study with a 1-year follow-up. Arch Phys Med Rehabil 2005; 86:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/44\">",
"      Ben Salah Frih Z, Fendri Y, Jellad A, et al. Efficacy and treatment compliance of a home-based rehabilitation programme for chronic low back pain: a randomized, controlled study. Ann Phys Rehabil Med 2009; 52:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/45\">",
"      Shirado O, Doi T, Akai M, et al. Multicenter randomized controlled trial to evaluate the effect of home-based exercise on patients with chronic low back pain: the Japan low back pain exercise therapy study. Spine (Phila Pa 1976) 2010; 35:E811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/46\">",
"      Waller B, Lambeck J, Daly D. Therapeutic aquatic exercise in the treatment of low back pain: a systematic review. Clin Rehabil 2009; 23:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/47\">",
"      Medina-Mirapeix F, Escolar-Reina P, Gasc&oacute;n-C&aacute;novas JJ, et al. Personal characteristics influencing patients' adherence to home exercise during chronic pain: a qualitative study. J Rehabil Med 2009; 41:347.",
"     </a>",
"    </li>",
"    <li>",
"     Bigos S, Bower O, Braen G, et al. Acute Low Back Problems in Adults, Clinical Practice Guideline No. 14. Agency for Health Care Policy and Research; US Department of Health and Human Services, Rockville, MD 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/49\">",
"      van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain. A systematic review of randomized controlled trials of the most common interventions. Spine (Phila Pa 1976) 1997; 22:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/50\">",
"      Waddell G. Biopsychosocial analysis of low back pain. Baillieres Clin Rheumatol 1992; 6:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/51\">",
"      Guzm&aacute;n J, Esmail R, Karjalainen K, et al. Multidisciplinary bio-psycho-social rehabilitation for chronic low back pain. Cochrane Database Syst Rev 2002; :CD000963.",
"     </a>",
"    </li>",
"    <li>",
"     Glass LS, Harris JS, Blais BR, et al. Occupational Medicine Practice Guidelines: Evaluation and Management of Common Health Problems and Functional Recovery of Workers, 2nd ed, OEM Press, Beverly Farms, MA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/53\">",
"      Haig AJ, Tong HC, Yamakawa KS, et al. Spinal stenosis, back pain, or no symptoms at all? A masked study comparing radiologic and electrodiagnostic diagnoses to the clinical impression. Arch Phys Med Rehabil 2006; 87:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/54\">",
"      Pfirrmann CW, Metzdorf A, Elfering A, et al. Effect of aging and degeneration on disc volume and shape: A quantitative study in asymptomatic volunteers. J Orthop Res 2006; 24:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/55\">",
"      van Rijn JC, Klemetso N, Reitsma JB, et al. Symptomatic and asymptomatic abnormalities in patients with lumbosacral radicular syndrome: Clinical examination compared with MRI. Clin Neurol Neurosurg 2006; 108:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/56\">",
"      Weiner DK, Haggerty CL, Kritchevsky SB, et al. How does low back pain impact physical function in independent, well-functioning older adults? Evidence from the Health ABC Cohort and implications for the future. Pain Med 2003; 4:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/57\">",
"      Jarvik JG, Deyo RA. Diagnostic evaluation of low back pain with emphasis on imaging. Ann Intern Med 2002; 137:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/58\">",
"      Albert HB, Manniche C. The efficacy of systematic active conservative treatment for patients with severe sciatica: a single-blind, randomized, clinical, controlled trial. Spine (Phila Pa 1976) 2012; 37:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/59\">",
"      Ostelo RW, de Vet HC, Waddell G, et al. Rehabilitation following first-time lumbar disc surgery: a systematic review within the framework of the cochrane collaboration. Spine (Phila Pa 1976) 2003; 28:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/60\">",
"      McNeely ML, Torrance G, Magee DJ. A systematic review of physiotherapy for spondylolysis and spondylolisthesis. Man Ther 2003; 8:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/61\">",
"      Burton AK, Balagu&eacute; F, Cardon G, et al. How to prevent low back pain. Best Pract Res Clin Rheumatol 2005; 19:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6841/abstract/62\">",
"      Choi BK, Verbeek JH, Tam WW, Jiang JY. Exercises for prevention of recurrences of low-back pain. Cochrane Database Syst Rev 2010; :CD006555.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7774 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-6BEDC4A8C2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6841=[""].join("\n");
var outline_f6_43_6841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGIC BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXERCISE FOR ACUTE LBP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXERCISE FOR SUBACUTE AND CHRONIC LBP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Timing and dosage of exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specific exercise programs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Core strengthening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - McKenzie method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Alexander technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mind body exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1281041167\">",
"      Yoga",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1281041174\">",
"      Pilates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1281041188\">",
"      Tai chi",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Home-based programs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aquatic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Back schools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Functional restoration programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Compliance with exercise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Psychosocial barriers to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Multidisciplinary rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DISEASE SPECIFIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Lumbar spinal stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lumbosacral radiculopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Following lumbar disc surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Spondylolysis and spondylolisthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVENTION OF LBP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/7774\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7774|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?37/1/37918\" title=\"algorithm 1\">",
"      Exercise prescript schema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/7774|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/54/26475\" title=\"table 1\">",
"      Red flag symptoms of low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/33/5655?source=related_link\">",
"      Acute lumbosacral radiculopathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/21/12633?source=related_link\">",
"      Diagnostic testing for low back pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/15/22776?source=related_link\">",
"      Lumbar spinal stenosis: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8169?source=related_link\">",
"      Musculoskeletal injury in the young athlete: Overview of rehabilitation for nonoperative injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14072?source=related_link\">",
"      Occupational low back pain: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41222?source=related_link\">",
"      Spinal manipulation in the treatment of musculoskeletal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34905?source=related_link\">",
"      Subacute and chronic low back pain: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6842="Molluscum contagiosum";
var content_f6_43_6842=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Molluscum contagiosum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Stuart N Isaacs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Ted Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/43/6842/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/43/6842/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum is a poxvirus that causes a chronic localized infection, consisting of flesh-colored, dome-shaped papules on the skin of an infected individual. The epidemiology, clinical features, diagnosis, and management of molluscum contagiosum will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum is a member of the poxvirus family but is in a different genus from the orthopoxviruses (variola, vaccinia, and monkeypox viruses) discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=see_link\">",
"     \"Vaccinia virus as the smallpox vaccine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16439?source=see_link\">",
"     \"Monkeypox\"",
"    </a>",
"    ). Molluscum contagiosum causes a chronic localized infection with small papules on the skin of an infected individual in contrast to the acute, sometimes fatal, disease induced by smallpox.",
"   </p>",
"   <p>",
"    Information about molluscum contagiosum at the molecular level has been hampered by the inability to grow the virus in standard cell culture or in an animal model of infection. While there are reports of some success in growth using human foreskin xenograft fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/1\">",
"     1",
"    </a>",
"    ], a major breakthrough came when the entire 190,000 base pair genome of the molluscum contagiosum virus was sequenced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like variola and vaccinia viruses, molluscum contagiosum replicates in the cytoplasm of cells, and thus, it is not surprising that more than one-half of the genes are similar to those found in variola and vaccinia viruses. However, since the diseases induced are quite different [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/4\">",
"     4",
"    </a>",
"    ], it also is not surprising that many genes found in variola and vaccinia are not present in the molluscum contagiosum genome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Molluscum contagiosum contains many unique genes that encode proteins responsible for novel host defense mechanisms; these mechanisms inhibit the host inflammatory and immune responses to the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum infection has been reported worldwide. Although four distinct genotypes have been identified, genotype 1 predominates and represents 90 percent of cases in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/8\">",
"     8",
"    </a>",
"    ]. A population-based Australian seroepidemiology study in 357 people revealed an overall seropositivity rate of 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/9\">",
"     9",
"    </a>",
"    ]. The data also indicated that very mild or subclinical cases may be more common in the general community than previously suspected.",
"   </p>",
"   <p>",
"    It is estimated that fewer than 5 percent of children in the United States have clinical evidence of molluscum contagiosum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/8\">",
"     8",
"    </a>",
"    ]. The number of cases in adults has varied over time. In the 1980s, the number of molluscum contagiosum cases increased, apparently as a result of the acquired immune deficiency syndrome (AIDS) epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/10\">",
"     10",
"    </a>",
"    ]; however, since the introduction of highly active antiretroviral therapy (HAART), the number of molluscum contagiosum cases in AIDS patients has decreased substantially [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum is a common disease of childhood. The disease also occurs in healthy adolescents and adults, often as a sexually transmitted disease or in relation to participation in contact sports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/8\">",
"     8",
"    </a>",
"    ]. Molluscum contagiosum is also associated with immunodeficient states. It can occur in the setting of underlying cellular immunodeficiency, such as in human immunodeficiency virus (HIV) infection, or during treatment with immunosuppressive drugs.",
"   </p>",
"   <p>",
"    Although it has been proposed that atopic dermatitis is a risk factor for molluscum contagiosum (",
"    <a class=\"graphic graphic_picture graphicRef57836 \" href=\"UTD.htm?19/54/20323\">",
"     picture 1F",
"    </a>",
"    ), data conflict on the relationship between these diseases. An increased risk is suggested by studies that report prevalence rates for atopic dermatitis between 18 and 45 percent among patients with molluscum contagiosum, rates that exceed the estimated prevalence of atopic dermatitis in the general pediatric population (10 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/12\">",
"     12",
"    </a>",
"    ]. It is theorized that the relative suppression of T-helper cell type 1 responses in acute skin lesions of atopic dermatitis could contribute to a predisposition for molluscum contagiosum in the atopic dermatitis population.",
"   </p>",
"   <p>",
"    In contrast to the assertion that atopic dermatitis is a risk factor for this infection, a nursery school-based study of over 1100 children in Japan failed to find a statistically significant increase in molluscum contagiosum among children who had a history of atopic dermatitis compared with children without atopic dermatitis (odds ratio 1.64, 95% CI 1.00-2.68) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, the relationship between atopic dermatitis and molluscum contagiosum remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like many viruses in the poxvirus family, molluscum contagiosum is spread by direct skin-to-skin contact and thus can occur anywhere on the body. The virus can be transmitted via autoinoculation by scratching or touching a lesion. For example, if the lesions develop on the face, shaving may spread the virus. The only known host for molluscum contagiosum is humans.",
"   </p>",
"   <p>",
"    Infection can also be spread via fomites on bath sponges or towels or through skin contact during participation in contact sports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/8\">",
"     8",
"    </a>",
"    ]. An association of molluscum contagiosum with swimming pool use also has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/14\">",
"     14",
"    </a>",
"    ]. When it occurs in the genital region in sexually active individuals, molluscum contagiosum is classified as a sexually transmitted disease. In contrast, autoinoculation, rather than sexual contact, is responsible for most anogenital lesions in children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Estimates for the incubation period of the virus vary from one week to six months, but it is typically characterized&nbsp;as being between two and six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The molluscum contagiosum virus causes a chronic localized infection characterized by firm, dome shaped papules on the skin (",
"    <a class=\"graphic graphic_picture graphicRef55247 graphicRef68001 graphicRef56699 graphicRef81042 graphicRef59150 graphicRef57836 \" href=\"UTD.htm?43/13/44250\">",
"     picture 1A-F",
"    </a>",
"    ). Lesions are often 2 to 5 mm in diameter, with a shiny surface and central indentation or umbilication. Occasionally, the growths can be polypoid with a stalk-like base. Pruritus may be present or absent, and lesions sometimes become visibly inflamed.",
"   </p>",
"   <p>",
"    Molluscum contagiosum may appear anywhere on the body except the palms and soles. The most common areas of involvement include the trunk, axillae, antecubital and popliteal fossae, and crural folds. Lesions on the eyelid can cause conjunctivitis (",
"    <a class=\"graphic graphic_picture graphicRef75198 graphicRef66482 \" href=\"UTD.htm?29/46/30439\">",
"     picture 2A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/16\">",
"     16",
"    </a>",
"    ]. Oral mucosal involvement is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/17\">",
"     17",
"    </a>",
"    ]. Sexually transmitted molluscum contagiosum typically involves the groin, genitals, proximal thighs, and lower abdomen. In HIV-infected and other immunocompromised patients, lesions can be large (aka giant molluscum) and widespread (",
"    <a class=\"graphic graphic_picture graphicRef81275 graphicRef50976 \" href=\"UTD.htm?27/49/28441\">",
"     picture 3A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106808343\">",
"    <span class=\"h1\">",
"     ASSOCIATED CLINICAL FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106808350\">",
"    <span class=\"h2\">",
"     Molluscum dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum dermatitis, which is characterized by the development of eczematous patches or plaques surrounding molluscum contagiosum lesions, is a common phenomenon (",
"    <a class=\"graphic graphic_picture graphicRef86487 \" href=\"UTD.htm?30/47/31475\">",
"     picture 4",
"    </a>",
"    ). Estimates of the proportion of patients with molluscum who develop molluscum dermatitis have ranged from 9 to 47 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the use of topical corticosteroid therapy for molluscum dermatitis impacts the prognosis of molluscum contagiosum is unclear. Although there is some concern that local immunosuppression from topical corticosteroids could inhibit clearance of the infection, this has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. On the other hand, it is conceivable that untreated molluscum dermatitis could contribute to spread of the infection through scratching.",
"   </p>",
"   <p>",
"    A short course (eg, up to two weeks) of a low or medium potency topical corticosteroid (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 1",
"    </a>",
"    ) can be used to treat sites of molluscum dermatitis in patients in whom the condition is pruritic. Emollients may be used for the management of asymptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106808357\">",
"    <span class=\"h2\">",
"     Inflamed lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflamed molluscum contagiosum, which is characterized by erythema and swelling of individual lesions, is a clinical finding that may portend a higher likelihood of impending clinical improvement. In a retrospective study of 696 children with molluscum contagiosum, children with inflamed lesions were less likely to develop an increase in the number of lesions over the course of three months than patients who had neither inflamed lesions nor molluscum dermatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106808364\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gianotti-Crosti syndrome (also known as papular acrodermatitis) is a pruritic inflammatory skin condition that may occur in association with viral infections in children (",
"    <a class=\"graphic graphic_picture graphicRef67780 \" href=\"UTD.htm?10/9/10385\">",
"     picture 5",
"    </a>",
"    ). The face, buttocks, and extremities are common sites for lesion development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23097?source=see_link\">",
"     \"Gianotti-Crosti syndrome (papular acrodermatitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gianotti-Crosti like eruptions have been reported in patients with molluscum contagiosum. In one large retrospective study, this phenomenon was diagnosed in 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/12\">",
"     12",
"    </a>",
"    ]. Gianotti-Crosti like reactions may portend a higher likelihood of forthcoming clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of molluscum contagiosum is usually made by the characteristic appearance of the lesions (",
"    <a class=\"graphic graphic_picture graphicRef65763 \" href=\"UTD.htm?17/12/17600\">",
"     picture 6",
"    </a>",
"    ). When necessary, histologic examination can confirm the clinical diagnosis. Hematoxylin and eosin staining of a molluscum contagiosum lesion typically reveals keratinocytes containing eosinophilic cytoplasmic inclusion bodies (also known as molluscum bodies or Henderson-Paterson bodies) (",
"    <a class=\"graphic graphic_picture graphicRef69493 \" href=\"UTD.htm?28/19/28983\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although usually not indicated, electron microscopy of biopsies demonstrates typical brick-shaped poxvirus particles. Electron microscopy can also identify infected cells that appear normal on light microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Skin lesions due to cryptococcosis, histoplasmosis, or Penicillium marneffei infection may resemble molluscum lesions (",
"    <a class=\"graphic graphic_picture graphicRef59025 graphicRef69214 graphicRef78902 graphicRef80674 graphicRef56450 \" href=\"UTD.htm?41/60/42954\">",
"     picture 8A-E",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/22\">",
"     22",
"    </a>",
"    ]. The possibility of these disorders should be considered in immunosuppressed patients. Other lesions that may be mistaken for molluscum contagiosum include flat warts, condyloma acuminatum, condylomata lata (",
"    <a class=\"graphic graphic_picture graphicRef77221 \" href=\"UTD.htm?31/57/32657\">",
"     picture 9",
"    </a>",
"    ), pyogenic granuloma (",
"    <a class=\"graphic graphic_picture graphicRef67395 \" href=\"UTD.htm?23/19/23859\">",
"     picture 10",
"    </a>",
"    ), adnexal tumors, Langerhans cell histiocytosis (",
"    <a class=\"graphic graphic_picture graphicRef69504 \" href=\"UTD.htm?4/56/4997\">",
"     picture 11",
"    </a>",
"    ), basal cell carcinoma (",
"    <a class=\"graphic graphic_picture graphicRef67350 \" href=\"UTD.htm?16/22/16739\">",
"     picture 12",
"    </a>",
"    ), and amelanotic melanoma. Skin biopsy is useful for distinguishing molluscum contagiosum from other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of disseminated histoplasmosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=see_link&amp;anchor=H26#H26\">",
"     \"Cryptococcal infection outside the central nervous system\", section on 'Nonmeningeal, nonpulmonary cryptococcosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and clinical manifestations of Penicillium marneffei infection\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3760193\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immunocompetent patients, individual lesions usually spontaneously resolve within two months and the infection often clears completely within several months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15,23\">",
"     15,23",
"    </a>",
"    ]. In a minority of cases, disease persists for a few years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15,23\">",
"     15,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H106808223\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies usually are not indicated in children with molluscum contagiosum. Sexually active adolescents and adults with genital lesions should be evaluated for the presence of other sexually transmitted diseases. Patients with extensive lesions should be tested for human immunodeficiency virus (HIV) infection, and the possibility of other immune system disorders should also be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The self-limited nature of molluscum contagiosum and the paucity of evidence that definitively supports therapeutic intervention has led to debate over the need for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797788\">",
"    <span class=\"h2\">",
"     Decision to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advantages of successful treatment include limitation of lesion spread to other sites, reduction of the risk of transmission to others, resolution of pruritus when present, and the prevention of scarring that can result from lesions that become inflamed, traumatized, or secondarily infected. Treatment may also reduce patient or parental psychological stress over the appearance of lesions. However, depending on the chosen therapy, treatment can be time consuming or can result in adverse effects such as pain, irritation, dyspigmentation, or scarring.",
"   </p>",
"   <p>",
"    In general, adolescents and adults with sexually-transmitted molluscum contagiosum should be treated to avoid spread of the disease to others. Early treatment is also indicated in the setting of immunocompromised individuals, in whom infections can become severe.",
"   </p>",
"   <p>",
"    For immunocompetent children with molluscum contagiosum, treatment is optional. We typically inform parents and guardians of the expected course of the disease without treatment and the potential adverse effects of each treatment option. In cases in which parents or guardians desire intervention, we proceed with therapy.",
"   </p>",
"   <p>",
"    Prior to treatment,",
"    <strong>",
"     a full skin examination should be performed",
"    </strong>",
"    on patients with molluscum to identify all lesions. Incomplete treatment may result in continued autoinoculation and failure to achieve cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797795\">",
"    <span class=\"h2\">",
"     Periocular lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The destructive methods and topical agents reviewed below should not be utilized on lesions involving the ocular mucosa or eyelids. Patients with symptomatic ocular lesions should be referred to an ophthalmologist for management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283428\">",
"    <span class=\"h1\">",
"     FIRST-LINE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strong evidence for the efficacy of any treatment for molluscum contagiosum is lacking. A 2009 systematic review of randomized trials that investigated the efficacy of treatments for nongenital molluscum contagiosum in healthy individuals found insufficient evidence to conclude that any treatment was definitively effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the absence of large placebo-controlled trials to support the efficacy of cryotherapy, curettage, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     cantharidin",
"    </a>",
"    , the rapid, clinically evident response associated with their use offers some support for their utility for the removal of individual lesions. The efficacy of podophyllotoxin is supported by data from a placebo-controlled randomized trial. Thus, when a trial of treatment is desired, we consider cryotherapy, curettage, cantharidin, and podophyllotoxin as first-line therapeutic options. The efficacy and safety of podophyllotoxin for molluscum contagiosum in young children have not been definitively established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421447\">",
"    <span class=\"h2\">",
"     Cryotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liquid nitrogen is used to perform cryotherapy. A cotton-tipped swab dipped in liquid nitrogen and applied to individual lesions for 6 to 10 seconds can be used to perform this technique [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cryotherapy was shown to be a rapidly effective therapy in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H421668\">",
"     'Comparative studies'",
"    </a>",
"    below.) Treatment is often well tolerated in adolescents and adults; however, the pain associated with cryotherapy can limit its use in young children, particularly if multiple lesions are present.",
"   </p>",
"   <p>",
"    Scarring and temporary or permanent hypopigmentation are potential adverse effects of cryotherapy. Hypopigmentation can be prominent in individuals with dark skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421454\">",
"    <span class=\"h2\">",
"     Curettage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Curettage involves the physical removal of molluscum contagiosum with a curette. The immediate resolution of lesions has led some clinicians to use this method as their preferred therapy for molluscum contagiosum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to a randomized trial that found that more than 80 percent of patients were cured after a single session of curettage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/28\">",
"     28",
"    </a>",
"    ], a prospective study of 73 children and adults treated with curettage found that 42 out of 64 patients (66 percent) were not cured after a single session, and 25 out of 55 (45 percent) failed to clear after two sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/29\">",
"     29",
"    </a>",
"    ]. Risk factors for treatment failure included a high number of lesions and concomitant atopic dermatitis. (See",
"    <a class=\"local\" href=\"#H421668\">",
"     'Comparative studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The discomfort and minor bleeding associated with this procedure can be disturbing for some children, and the possibility of the development of small, depressed scars should be discussed with patients or their guardians prior to proceeding. Treatment may be time-consuming due to the need to ease children&rsquo;s fears about the procedure. Topical anesthetics applied prior to curettage can reduce discomfort and facilitate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=see_link\">",
"     \"Topical anesthetics in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421482\">",
"    <span class=\"h2\">",
"     Cantharidin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     Cantharidin",
"    </a>",
"    is a topical blistering agent that is commonly used for the treatment of molluscum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/30\">",
"     30",
"    </a>",
"    ]. Treatment should be performed by a clinician; patients should not be given cantharidin to apply at home. The expected response is the development of a small blister at the treatment site, followed by disappearance of the molluscum lesion and healing without scarring.",
"   </p>",
"   <p>",
"    In a retrospective study of 300 children treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     cantharidin",
"    </a>",
"    for molluscum, 90 percent of children had lesion clearance, and 8 percent demonstrated improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/31\">",
"     31",
"    </a>",
"    ]. On average, 2.1 clinician visits were necessary to achieve complete clearance. The parents of the patients appeared satisfied with treatment; 95 percent stated that they would be willing to have their child treated again with cantharidin.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     Cantharidin",
"    </a>",
"    is applied directly to lesions; the blunt wooden end of a cotton swab can be used for application. The site is then covered, such as with a bandage, to avoid inadvertent spread of the vesicant to other areas. Cantharidin should be washed off with soap and water two to six hours after application or at the first sign of blistering [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15\">",
"     15",
"    </a>",
"    ]. Occasionally blistering can be exuberant, and it is reasonable to treat a small number of lesions at the first visit. The duration of application can be adjusted based upon the initial response.",
"   </p>",
"   <p>",
"    Treatments can be repeated every two to four weeks until all lesions have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/31\">",
"     31",
"    </a>",
"    ]. In general, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     cantharidin",
"    </a>",
"    should be avoided on the face, genital, or perianal areas.",
"   </p>",
"   <p>",
"    Common adverse effects include transient burning, pain, erythema, and pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/31\">",
"     31",
"    </a>",
"    ]. Postinflammatory dyspigmentation may occur, but typically resolves over several months. While uncommon, scarring can occur as a consequence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"     cantharidin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283409\">",
"    <span class=\"h2\">",
"     Podophyllotoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Podophyllotoxin is an antimitotic agent that is commercially available as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/34/23074?source=see_link\">",
"     podofilox",
"    </a>",
"    0.5% (Condylox&reg;) in a solution or gel. The efficacy of podophyllotoxin was explored in a randomized trial of 150 males (ages 10 to 26 years); most lesions were located on the thighs or genitalia. Patients in the trial applied 0.5% podophyllotoxin cream, 0.3% podophyllotoxin cream, or placebo twice daily for three consecutive days per week [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/33\">",
"     33",
"    </a>",
"    ]. Treatment was continued for up to four weeks. By the end of treatment, the superiority of 0.5% podophyllotoxin was evident; 92, 52, and 16 percent of patients in the 0.5% podophyllotoxin, 0.3% podophyllotoxin, and placebo groups were cured, respectively.",
"   </p>",
"   <p>",
"    Local erythema, burning, pruritus, inflammation, and erosions can occur with the use of this agent. The safety and efficacy of podophyllotoxin for molluscum contagiosum have not been definitively established in young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283833\">",
"    <span class=\"h1\">",
"     SECOND-LINE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    and potassium hydroxide typically are applied for multiple weeks, a period during which spontaneous resolution is not unusual. Thus, observational studies have limited value for determining the efficacy of these treatments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421647\">",
"    <span class=\"h2\">",
"     Imiquimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    , a topical immunomodulator that induces the local production of proinflammatory cytokines, may have efficacy for the treatment for molluscum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A 2006 review of uncontrolled studies, case reports, and a placebo-controlled randomized trial found that imiquimod led to complete clearance in 35 out of 83 patients (42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/34\">",
"     34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In the randomized trial (n = 23),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    5% cream (applied three times per week for up to 12 weeks) was compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/37\">",
"     37",
"    </a>",
"    ]. By week 12, significantly more patients in the imiquimod group achieved partial clearance (defined as a &ge;30 percent decrease in lesion count) than in the placebo group (67 versus 18 percent). A higher percentage of patients in the imiquimod group also achieved complete clearance (33 versus 9 percent); however, this difference was not statistically significant. The lack of statistical significance may have been related to the small size of the trial; larger placebo-controlled trials are necessary to investigate the efficacy of imiquimod. &nbsp;",
"   </p>",
"   <p>",
"    In a subsequent randomized trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    was shown to be as effective as cryotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/27\">",
"     27",
"    </a>",
"    ]. Other agents have also been compared to imiquimod. (See",
"    <a class=\"local\" href=\"#H421668\">",
"     'Comparative studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     Imiquimod",
"    </a>",
"    is usually applied on three nonconsecutive nights per week and is washed off in the morning; treatment regimens with application five or seven days per week have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/28,34\">",
"     28,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Erythema and pruritus at application sites are common adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/38\">",
"     38",
"    </a>",
"    ]. The drug appears to be well tolerated in children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/38\">",
"     38",
"    </a>",
"    ]. The high cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    is a deterrent to use for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284164\">",
"    <span class=\"h2\">",
"     Potassium hydroxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potassium hydroxide (KOH), in concentrations of 5 or 10%, has been used for molluscum contagiosum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. Application frequency reported in the literature ranges from three times per week to twice daily.",
"   </p>",
"   <p>",
"    In a randomized trial in which 20 children were treated with either 10% KOH or normal saline (applied twice daily until signs of inflammation), 7 out of 10 patients treated with KOH cleared completely (average time to clearance 54 days), while only 2 out of 10 in the placebo group were cured [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/39\">",
"     39",
"    </a>",
"    ]. The difference between the two groups was not significant; thus, larger placebo-controlled randomized trials are necessary to evaluate the efficacy of this agent.",
"   </p>",
"   <p>",
"    In a separate series of 20 children treated twice daily with 5% KOH in an aqueous solution, all patients cleared within six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/41\">",
"     41",
"    </a>",
"    ]. Treatment with KOH also has been compared to other therapies for molluscum in randomized trials;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    and KOH appear to have similar efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H421668\">",
"     'Comparative studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Stinging or burning sensations often accompany application of KOH [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/42\">",
"     42",
"    </a>",
"    ], and may be reduced with the use of the 5% concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/40\">",
"     40",
"    </a>",
"    ]. Temporary dyspigmentation is another potential adverse effect of this therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283994\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284684\">",
"    <span class=\"h2\">",
"     Salicylic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salicylic acid is a widely available keratolytic that has been used in the treatment of molluscum contagiosum. In a randomized trial of 124 children, an agent containing salicylic acid 16.7% and lactic acid 16.7% (Duofilm&reg;) applied with a tooth pick at home three times per week was compared to three other treatments (see",
"    <a class=\"local\" href=\"#H421668\">",
"     'Comparative studies'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/28\">",
"     28",
"    </a>",
"    ]. Compared with curettage, patients treated with salicylic acid were more likely to return to the office, which they were instructed to do if lesions persisted. Adverse effects were frequent; 54 percent of patients treated with",
"    <span class=\"nowrap\">",
"     salicylic/lactic",
"    </span>",
"    acid experienced side effects. Local irritation is common with the use of salicylic acid.",
"   </p>",
"   <p>",
"    Use of salicylic acid in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/34/16933?source=see_link\">",
"     sodium nitrite",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/44\">",
"     44",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    solution [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/45\">",
"     45",
"    </a>",
"    ] has also been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5284328\">",
"    <span class=\"h2\">",
"     Topical retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tretinoin (0.5% cream, 0.1% cream, or 0.025% gel),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/60/17348?source=see_link\">",
"     adapalene",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    have been used for the treatment of molluscum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/46-49\">",
"     46-49",
"    </a>",
"    ]. The mechanism of action is thought to involve the induction of local irritation which damages the viral protein-lipid membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/50\">",
"     50",
"    </a>",
"    ]. Data on the efficacy of these agents are limited to reports of clinical experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/46-49\">",
"     46-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with topical retinoids can begin every other day and can be increased to twice daily as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15\">",
"     15",
"    </a>",
"    ]. Application is discontinued once local erythema develops [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/15\">",
"     15",
"    </a>",
"    ]. Irritation and xerosis are expected side effects. Topical retinoids should not be used during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H422717\">",
"    <span class=\"h2\">",
"     Other topical agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A paste containing 40%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    was reported to be effective in a series of 389 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/51\">",
"     51",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/14/27875?source=see_link\">",
"     phenol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/52\">",
"     52",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/24,53\">",
"     24,53",
"    </a>",
"    ] also have been used for molluscum contagiosum, but high risks for pain and scarring make these agents unfavorable options.",
"   </p>",
"   <p>",
"    ZymaDerm&trade; is a nonprescription topical homeopathic agent that is marketed for the treatment of molluscum contagiosum. No published studies have evaluated the efficacy and safety of ZymaDerm&trade; for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5283552\">",
"    <span class=\"h2\">",
"     Other physical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed dye lasers have shown efficacy in case reports and small uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/54-60\">",
"     54-60",
"    </a>",
"    ]. In a prospective study of 19 children treated with a 585 nm pulsed dye laser, a single treatment led to disease resolution in 84 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/54\">",
"     54",
"    </a>",
"    ]. Use of topical anesthetics prior to pulsed dye laser treatment may help to reduce pain associated with laser therapy. Potassium titanyl phosphate (KTP) lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/61\">",
"     61",
"    </a>",
"    ], carbon dioxide lasers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/62,63\">",
"     62,63",
"    </a>",
"    ], and photodynamic therapy have also been used to treat lesions.",
"   </p>",
"   <p>",
"    Additional physical interventions that have been reported in the treatment of molluscum contagiosum include electrodessication, manual extrusion of the central core by squeezing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/52\">",
"     52",
"    </a>",
"    ], removal with sterilized tweezers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/64\">",
"     64",
"    </a>",
"    ], needle penetration in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"     topical tretinoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/65\">",
"     65",
"    </a>",
"    ], intralesional injection with",
"    <em>",
"     Candida",
"    </em>",
"    antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/66\">",
"     66",
"    </a>",
"    ], and topical 20 to 35%",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/39/7794?source=see_link\">",
"     trichloroacetic acid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/67\">",
"     67",
"    </a>",
"    ]. The efficacy and safety of these interventions have not been studied in randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421654\">",
"    <span class=\"h2\">",
"     Oral cimetidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     Cimetidine",
"    </a>",
"    is an H",
"    <sub>",
"     2",
"    </sub>",
"    antihistamine that has also been found to have immunomodulatory properties. Data conflict on the efficacy of this agent for molluscum contagiosum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. In a series of 13 children with molluscum contagiosum who had failed to respond to other therapies, treatment with cimetidine (40",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for two months) was associated with clearance of all lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/69\">",
"     69",
"    </a>",
"    ]. However, in a separate series of 14 children treated with cimetidine 40",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    only four children cleared within three months, and seven children showed no improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/68\">",
"     68",
"    </a>",
"    ]. Three children who did not take cimetidine due to the taste of the medicine or treatment cost spontaneously improved within three months, raising questions about the efficacy of treatment. Additional studies are necessary to investigate the efficacy of cimetidine in the management of molluscum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421668\">",
"    <span class=\"h1\">",
"     COMPARATIVE STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few trials that compare the efficacy of treatments for molluscum. Examples of the available data include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Multiple therapies &ndash;",
"      </strong>",
"      A randomized trial of 124 children (ages 1 to 16 years) compared the safety and efficacy of curettage with topical anesthesia,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"       cantharidin",
"      </a>",
"      0.7% (applied for two to four hours), a combination product with 16.7% salicylic acid and 16.7% lactic acid (three times per week), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      5% cream (three times per week) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/28\">",
"       28",
"      </a>",
"      ]. Ten lesions on each patient were treated according to protocol, and the remaining lesions on all patients were treated with curettage. Curettage required the fewest follow-up visits for resolution of all 10 lesions, with 81 percent of patients requiring only one visit. Cantharidin,",
"      <span class=\"nowrap\">",
"       salicylic/lactic",
"      </span>",
"      acid, and imiquimod required only one visit 37, 54, and 57 percent of the time, respectively. Parent and patient satisfaction with treatment was highest in the curettage group (87 percent), followed by cantharidin (60 percent), imiquimod (45 percent), and",
"      <span class=\"nowrap\">",
"       salicylic/lactic",
"      </span>",
"      acid (32 percent). Adverse effects were most common in the group treated with salicylic acid (53 percent of patients).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      <strong>",
"       versus cryotherapy &ndash;",
"      </strong>",
"      Imiquimod (applied five days per week) was compared to cryotherapy (once weekly) in a randomized trial of 74 children with molluscum contagiosum [",
"      <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/27\">",
"       27",
"      </a>",
"      ]. Treatment with either regimen was continued until lesion resolution or for up to 16 weeks. Cryotherapy led to complete cure in all patients and more rapid resolution than imiquimod; the majority of children (26 out of 37; 70 percent) were cured within three weeks. In the imiquimod group, 34 of 37 (92 percent) achieved complete cure, with the majority (22 out of 37; 59 percent) clearing within six weeks. The difference in complete cure rates between the two groups was not statistically significant. However, adverse effects (pain, bullae, dyspigmentation, mild scarring) were more common in cryotherapy group",
"      <strong>",
"       .",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      <strong>",
"       verus KOH &ndash;",
"      </strong>",
"      Two randomized trials have compared the efficacy of imiquimod 5% cream and 10% potassium hydroxide (KOH). The trials did not find significant differences in efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a randomized trial of 30 patients with molluscum contagiosum (ages 1 to 36 years), patients were treated with either agent three nights per week until lesion clearance or for up to 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/43\">",
"       43",
"      </a>",
"      ]. Statistically significant reductions in lesion counts were observed in both groups, but a statistically significant difference in efficacy between the two treatments was not detected. In the trial, 8 out of 14 patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      (57 percent) and 10 out of 13 patients treated with KOH (77 percent) achieved complete clearance. All patients who achieved complete responses cleared within eight weeks.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       Imiquimod",
"      </a>",
"      and 10% KOH were found to be equally effective for achieving disease clearance in another randomized trial in which patients (ages 2 to 32 years) were treated with either agent three times weekly; all lesions resolved within 12 weeks in 8 out of 18 patients given imiquimod (44 percent) and 8 out of 19 of patients given KOH (42 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/42\">",
"       42",
"      </a>",
"      ]. Compared with imiquimod, KOH appeared to have a more rapid onset of action and a higher rate of adverse effects (56 versus 78 percent developed side effects). The most common side effects observed were erythema and crusting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5282851\">",
"    <span class=\"h1\">",
"     IMMUNOCOMPROMISED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocompromised patients can develop severe, persistent cases of molluscum contagiosum. Therapies that result in wounds, such as curettage, may be a less favorable option for immunocompromised patients because of an elevated risk for infection.",
"   </p>",
"   <p>",
"    Successful treatment of severe, refractory molluscum contagiosum in immunocompromised patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    has been reported in multiple patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/35,49,70-72\">",
"     35,49,70-72",
"    </a>",
"    ]. Similar to the use of the drug in immunocompetent patients, imiquimod is usually applied three nights weekly. (See",
"    <a class=\"local\" href=\"#H421647\">",
"     'Imiquimod'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In addition to the treatments above, immunocompromised patients with refractory disease have been treated with agents such as interferon alpha and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421689\">",
"    <span class=\"h2\">",
"     Interferon alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunodeficient children and adults have attained resolution of severe, refractory lesions with subcutaneous interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. The use of intralesional interferon alpha has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Influenza-like symptoms are common adverse effects of interferon therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421696\">",
"    <span class=\"h2\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/77-79\">",
"     77-79",
"    </a>",
"    ] and topical cidofovir (1% or 3%) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/78,80-83\">",
"     78,80-83",
"    </a>",
"    ] have been used in immunocompromised patients with severe, refractory molluscum.",
"   </p>",
"   <p>",
"    Renal toxicity is a significant concern with the use of systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    . Local irritation and painful cutaneous erosions can occur after application of the topical form [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/82\">",
"     82",
"    </a>",
"    ]. Due to the absence of a commercial product, preparation of topical cidofovir must be entrusted to a compounding pharmacy. The stability, bioavailability, and optimal dosing regimen&nbsp;of such extemporaneous mixtures are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797087\">",
"    <span class=\"h2\">",
"     HAART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recovery of immune function may result in improvement. In HIV-infected patients, there have been multiple reports of recalcitrant molluscum contagiosum lesions resolving only after initiation of highly active antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/11,84\">",
"     11,84",
"    </a>",
"    ]. However, the development of molluscum contagiosum has also been reported in association with immune reconstitution inflammatory syndrome (IRIS) in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421762\">",
"    <span class=\"h1\">",
"     SCHOOL AND SPORTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not necessary to remove children with molluscum contagiosum from daycare or school; however, care should be taken to reduce the risk of transmission to others. Lesions in areas that are likely to come in contact with others should be covered with clothing or a watertight bandage. Bathing with other children should be avoided and towels and sponges should not be shared.",
"   </p>",
"   <p>",
"    Affected individuals do not need to be excluded from contact sports activities provided lesions can be covered with clothing or bandages. Individuals with molluscum contagiosum should not be restricted from the use of public swimming pools.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H421776\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molluscum contagiosum in pregnancy is not common and the vertical transmission rate is not known. Only a small number of cases of congenital transmission have been documented in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since molluscum contagiosum is spread by direct contact, a woman with genital lesions at the time of a vaginal delivery could theoretically transmit molluscum to her newborn, as is seen with genital warts. However, studies that have examined the incidence of molluscum contagiosum in children reveal that it is extremely uncommon to find molluscum contagiosum in children under the age of one [",
"    <a class=\"abstract\" href=\"UTD.htm?6/43/6842/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. The lack of many cases in this age group may indicate that infants are protected by passive maternal antibodies or that the infection has a very long incubation period.",
"   </p>",
"   <p>",
"    There are scant data regarding the management of molluscum contagiosum in pregnancy since it is uncommonly encountered. Due to the toxicity of the chemicals commonly used to treat molluscum contagiosum (eg, podophyllotoxin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"     imiquimod",
"    </a>",
"    ), we do not recommend their use during pregnancy. Other options include cryotherapy or curettage or no treatment, since molluscum contagiosum is a self-limited disease. Dressings to cover visible lesions during delivery (eg, Tegaderm) may be considered to avoid skin-to-skin contact and hopefully lessen the risk of transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/35/43583?source=see_link\">",
"       \"Patient information: Molluscum contagiosum (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8725830\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Molluscum contagiosum is a poxvirus that causes localized skin infections. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Virology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molluscum contagiosum is commonly seen in children, but can also occur in adults. The virus is transmitted through direct skin contact or fomites. Molluscum contagiosum infection in the genital region may result from transmission during sexual activity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period for molluscum contagiosum is uncertain, but has been estimated to be between two and six weeks. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molluscum contagiosum most commonly presents as single or multiple small, flesh-colored papules with central umbilication (",
"      <a class=\"graphic graphic_picture graphicRef55247 graphicRef68001 graphicRef56699 graphicRef81042 graphicRef59150 graphicRef57836 \" href=\"UTD.htm?43/13/44250\">",
"       picture 1A-F",
"      </a>",
"      ). Immunosuppressed individuals have an increased risk for larger lesions and more widespread disease (",
"      <a class=\"graphic graphic_picture graphicRef81275 graphicRef50976 \" href=\"UTD.htm?27/49/28441\">",
"       picture 3A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of molluscum contagiosum typically is based upon the clinical appearance of skin lesions. Biopsy can confirm the diagnosis when necessary. Histopathologic examination of a lesion of molluscum contagiosum reveals eosinophilic cytoplasmic inclusion bodies within keratinocytes (",
"      <a class=\"graphic graphic_picture graphicRef69493 \" href=\"UTD.htm?28/19/28983\">",
"       picture 7",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Molluscum contagiosum infection is usually self-limited in immunocompetent individuals, and electing not to treat is a satisfactory option. In general, molluscum in the genital region should be treated due to the potential for sexual transmission. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High quality data on the efficacy of treatments for molluscum contagiosum are limited. When a trial of treatment is desired, we suggest the use of cryotherapy, curettage,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/57/8083?source=see_link\">",
"       cantharidin",
"      </a>",
"      , or podophyllotoxin over other therapies (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The use of cantharidin should be avoided in the genital area. The efficacy and safety of podophyllotoxin for molluscum contagiosum in children has not been definitively established. (See",
"      <a class=\"local\" href=\"#H5283428\">",
"       'First-line therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prominent hypopigmentation may result from treatment with cryotherapy in patients with dark skin. The risks and benefits of cryotherapy should be considered carefully in these patients. (See",
"      <a class=\"local\" href=\"#H421447\">",
"       'Cryotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Topical agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/59/20406?source=see_link\">",
"       imiquimod",
"      </a>",
"      , potassium hydroxide (KOH), salicylic acid, and topical retinoids have also been used for the treatment of molluscum contagiosum. However, treatment for multiple weeks is typically required, and the possibility of spontaneous resolution during this time period contributes to uncertainty about the benefit of these agents. &nbsp;(See",
"      <a class=\"local\" href=\"#H5283833\">",
"       'Second-line therapies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5283994\">",
"       'Other therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      for molluscum contagiosum is uncertain. Cimetidine should not be used as a first-line therapy for molluscum contagiosum. (See",
"      <a class=\"local\" href=\"#H421654\">",
"       'Oral cimetidine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immunocompromised patients are at risk for extensive and persistent disease. Improvement in molluscum contagiosum may occur in patients with human immunodeficiency virus (HIV) infection after the initiation of antiretroviral therapy. (See",
"      <a class=\"local\" href=\"#H5282851\">",
"       'Immunocompromised patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with molluscum contagiosum should not be excluded from daycare or school. Lesions should be covered with clothing or a bandage to reduce the risk of transmission to others. (See",
"      <a class=\"local\" href=\"#H421762\">",
"       'School and sports'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/1\">",
"      Fife KH, Whitfeld M, Faust H, et al. Growth of molluscum contagiosum virus in a human foreskin xenograft model. Virology 1996; 226:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/2\">",
"      Senkevich TG, Bugert JJ, Sisler JR, et al. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 1996; 273:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/3\">",
"      Senkevich TG, Koonin EV, Bugert JJ, et al. The genome of molluscum contagiosum virus: analysis and comparison with other poxviruses. Virology 1997; 233:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/4\">",
"      Bugert JJ, Darai G. Recent advances in molluscum contagiosum virus research. Arch Virol Suppl 1997; 13:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/5\">",
"      Damon I, Murphy PM, Moss B. Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc Natl Acad Sci U S A 1998; 95:6403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/6\">",
"      Senkevich TG, Moss B. Domain structure, intracellular trafficking, and beta2-microglobulin binding of a major histocompatibility complex class I homolog encoded by molluscum contagiosum virus. Virology 1998; 250:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/7\">",
"      Shisler JL, Senkevich TG, Berry MJ, Moss B. Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus. Science 1998; 279:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/8\">",
"      Dohil MA, Lin P, Lee J, et al. The epidemiology of molluscum contagiosum in children. J Am Acad Dermatol 2006; 54:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/9\">",
"      Konya J, Thompson CH. Molluscum contagiosum virus: antibody responses in persons with clinical lesions and seroepidemiology in a representative Australian population. J Infect Dis 1999; 179:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/10\">",
"      Koopman RJ, van Merri&euml;nboer FC, Vreden SG, Dolmans WM. Molluscum contagiosum; a marker for advanced HIV infection. Br J Dermatol 1992; 126:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/11\">",
"      Calista D, Boschini A, Landi G. Resolution of disseminated molluscum contagiosum with Highly Active Anti-Retroviral Therapy (HAART) in patients with AIDS. Eur J Dermatol 1999; 9:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/12\">",
"      Berger EM, Orlow SJ, Patel RR, Schaffer JV. Experience with molluscum contagiosum and associated inflammatory reactions in a pediatric dermatology practice: the bump that rashes. Arch Dermatol 2012; 148:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/13\">",
"      Hayashida S, Furusho N, Uchi H, et al. Are lifetime prevalence of impetigo, molluscum and herpes infection really increased in children having atopic dermatitis? J Dermatol Sci 2010; 60:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/14\">",
"      Braue A, Ross G, Varigos G, Kelly H. Epidemiology and impact of childhood molluscum contagiosum: a case series and critical review of the literature. Pediatr Dermatol 2005; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/15\">",
"      Brown J, Janniger CK, Schwartz RA, Silverberg NB. Childhood molluscum contagiosum. Int J Dermatol 2006; 45:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/16\">",
"      Schornack MM, Siemsen DW, Bradley EA, et al. Ocular manifestations of molluscum contagiosum. Clin Exp Optom 2006; 89:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/17\">",
"      Fornatora ML, Reich RF, Gray RG, Freedman PD. Intraoral molluscum contagiosum: a report of a case and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/18\">",
"      Osio A, Deslandes E, Saada V, et al. Clinical characteristics of molluscum contagiosum in children in a private dermatology practice in the greater Paris area, France: a prospective study in 661 patients. Dermatology 2011; 222:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/19\">",
"      Netchiporouk E, Cohen BA. Recognizing and managing eczematous id reactions to molluscum contagiosum virus in children. Pediatrics 2012; 129:e1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/20\">",
"      Cotell SL, Roholt NS. Images in clinical medicine. Molluscum contagiosum in a patient with the acquired immunodeficiency syndrome. N Engl J Med 1998; 338:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/21\">",
"      Smith KJ, Skelton HG 3rd, Yeager J, et al. Molluscum contagiosum. Ultrastructural evidence for its presence in skin adjacent to clinical lesions in patients infected with human immunodeficiency virus type 1. Military Medical Consortium for Applied Retroviral Research. Arch Dermatol 1992; 128:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/22\">",
"      Blanco P, Viallard JF, Beylot-Barry M, et al. Cutaneous cryptococcosis resembling molluscum contagiosum in a patient with non-Hodgkin's lymphoma. Clin Infect Dis 1999; 29:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/23\">",
"      Lee R, Schwartz RA. Pediatric molluscum contagiosum: reflections on the last challenging poxvirus infection, Part 1. Cutis 2010; 86:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/24\">",
"      Tyring SK. Molluscum contagiosum: the importance of early diagnosis and treatment. Am J Obstet Gynecol 2003; 189:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/25\">",
"      Bikowski JB Jr. Molluscum contagiosum: the need for physician intervention and new treatment options. Cutis 2004; 73:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/26\">",
"      van der Wouden JC, van der Sande R, van Suijlekom-Smit LW, et al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev 2009; :CD004767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/27\">",
"      Al-Mutairi N, Al-Doukhi A, Al-Farag S, Al-Haddad A. Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. Pediatr Dermatol 2010; 27:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/28\">",
"      Hanna D, Hatami A, Powell J, et al. A prospective randomized trial comparing the efficacy and adverse effects of four recognized treatments of molluscum contagiosum in children. Pediatr Dermatol 2006; 23:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/29\">",
"      Simonart T, De Maertelaer V. Curettage treatment for molluscum contagiosum: a follow-up survey study. Br J Dermatol 2008; 159:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/30\">",
"      Coloe J, Morrell DS. Cantharidin use among pediatric dermatologists in the treatment of molluscum contagiosum. Pediatr Dermatol 2009; 26:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/31\">",
"      Silverberg NB, Sidbury R, Mancini AJ. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients. J Am Acad Dermatol 2000; 43:503.",
"     </a>",
"    </li>",
"    <li>",
"     Piggott C, Friedlander SF, Tom W. Poxvirus infections. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz, SI, et al.  (Eds), McGraw-Hill, 2012. Vol 2, p.2402.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/33\">",
"      Syed TA, Lundin S, Ahmad M. Topical 0.3% and 0.5% podophyllotoxin cream for self-treatment of molluscum contagiosum in males. A placebo-controlled, double-blind study. Dermatology 1994; 189:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/34\">",
"      Arican O. Topical treatment of molluscum contagiosum with imiquimod 5% cream in Turkish children. Pediatr Int 2006; 48:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/35\">",
"      Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/36\">",
"      Skinner RB Jr. Treatment of molluscum contagiosum with imiquimod 5% cream. J Am Acad Dermatol 2002; 47:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/37\">",
"      Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 2004; 74:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/38\">",
"      Myhre PE, Levy ML, Eichenfield LF, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of molluscum contagiosum in children. Pediatr Dermatol 2008; 25:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/39\">",
"      Short KA, Fuller LC, Higgins EM. Double-blind, randomized, placebo-controlled trial of the use of topical 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Pediatr Dermatol 2006; 23:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/40\">",
"      Romiti R, Ribeiro AP, Grinblat BM, et al. Treatment of molluscum contagiosum with potassium hydroxide: a clinical approach in 35 children. Pediatr Dermatol 1999; 16:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/41\">",
"      Romiti R, Ribeiro AP, Romiti N. Evaluation of the effectiveness of 5% potassium hydroxide for the treatment of molluscum contagiosum. Pediatr Dermatol 2000; 17:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/42\">",
"      Metkar A, Pande S, Khopkar U. An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Indian J Dermatol Venereol Leprol 2008; 74:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/43\">",
"      Seo SH, Chin HW, Jeong DW, Sung HW. An open, randomized, comparative clinical and histological study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. Ann Dermatol 2010; 22:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/44\">",
"      Ormerod AD, White MI, Shah SA, Benjamin N. Molluscum contagiosum effectively treated with a topical acidified nitrite, nitric oxide liberating cream. Br J Dermatol 1999; 141:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/45\">",
"      Ohkuma M. Molluscum contagiosum treated with iodine solution and salicylic acid plaster. Int J Dermatol 1990; 29:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/46\">",
"      Papa CM, Berger RS. Venereal herpes-like molluscum contagiosum: treatment with tretinoin. Cutis 1976; 18:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/47\">",
"      Erdmann SM, R&uuml;bben A, Frank J, Poblete-Guti&eacute;rrez P. [Mollusca contagiosa in an infant with atopic eczema. A therapeutic challenge]. Hautarzt 2004; 55:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/48\">",
"      Scheinfeld N. Treatment of molluscum contagiosum: a brief review and discussion of a case successfully treated with adapelene. Dermatol Online J 2007; 13:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/49\">",
"      Lin HY, Linn G, Liu CB, et al. An immunocompromised woman with severe molluscum contagiosum that responded well to topical imiquimod: a case report and literature review. J Low Genit Tract Dis 2010; 14:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/50\">",
"      Lee R, Schwartz RA. Pediatric molluscum contagiosum: reflections on the last challenging poxvirus infection, Part 2. Cutis 2010; 86:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/51\">",
"      Niizeki K, Hashimoto K. Treatment of molluscum contagiosum with silver nitrate paste. Pediatr Dermatol 1999; 16:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/52\">",
"      Weller R, O'Callaghan CJ, MacSween RM, White MI. Scarring in Molluscum contagiosum: comparison of physical expression and phenol ablation. BMJ 1999; 319:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/53\">",
"      Garrett SJ, Robinson JK, Roenigk HH Jr. Trichloroacetic acid peel of molluscum contagiosum in immunocompromised patients. J Dermatol Surg Oncol 1992; 18:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/54\">",
"      Binder B, Weger W, Komericki P, Kopera D. Treatment of molluscum contagiosum with a pulsed dye laser: Pilot study with 19 children. J Dtsch Dermatol Ges 2008; 6:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/55\">",
"      Chatproedprai S, Suwannakarn K, Wananukul S, et al. Efficacy of pulsed dyed laser (585 nm) in the treatment of molluscum contagiosum subtype 1. Southeast Asian J Trop Med Public Health 2007; 38:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/56\">",
"      Michel JL. Treatment of molluscum contagiosum with 585 nm collagen remodeling pulsed dye laser. Eur J Dermatol 2004; 14:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/57\">",
"      Hancox JG, Jackson J, McCagh S. Treatment of molluscum contagiosum with the pulsed dye laser over a 28-month period. Cutis 2003; 71:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/58\">",
"      Nehal KS, Sarnoff DS, Gotkin RH, Friedman-Kien A. Pulsed dye laser treatment of molluscum contagiosum in a patient with acquired immunodeficiency syndrome. Dermatol Surg 1998; 24:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/59\">",
"      Hindson C, Cotterill J. Treatment of molluscum contagiosum with the pulsed tuneable dye laser. Clin Exp Dermatol 1997; 22:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/60\">",
"      Hughes PS. Treatment of molluscum contagiosum with the 585-nm pulsed dye laser. Dermatol Surg 1998; 24:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/61\">",
"      Dabis R, Rosbotham J, Jones L, et al. Potassium titanyl phosphate (KTP) laser treatment for molluscum contagiosum. J Dermatolog Treat 2006; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/62\">",
"      Amstey MS, Trombetta GC. Laser therapy for vulvar molluscum contagiosum infection. Am J Obstet Gynecol 1985; 153:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/63\">",
"      Gross G, Roussaki A, Brzoska J. Recalcitrant molluscum contagiosum in a patient with AIDS successfully treated by a combination of CO2-laser and natural interferon beta gel. Acta Derm Venereol 1998; 78:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/64\">",
"      Kakourou T, Zachariades A, Anastasiou T, et al. Molluscum contagiosum in Greek children: a case series. Int J Dermatol 2005; 44:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/65\">",
"      Godse K. Needling in molluscum contagiosum. J Eur Acad Dermatol Venereol 2006; 20:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/66\">",
"      Maronn M, Salm C, Lyon V, Galbraith S. One-year experience with candida antigen immunotherapy for warts and molluscum. Pediatr Dermatol 2008; 25:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/67\">",
"      Bard S, Shiman MI, Bellman B, Connelly EA. Treatment of facial molluscum contagiosum with trichloroacetic acid. Pediatr Dermatol 2009; 26:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/68\">",
"      Cunningham BB, Paller AS, Garzon M. Inefficacy of oral cimetidine for nonatopic children with molluscum contagiosum. Pediatr Dermatol 1998; 15:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/69\">",
"      Dohil M, Prendiville JS. Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients. Pediatr Dermatol 1996; 13:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/70\">",
"      Strauss RM, Doyle EL, Mohsen AH, Green ST. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS 2001; 12:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/71\">",
"      Brown CW Jr, O'Donoghue M, Moore J, Tharp M. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis 2000; 65:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/72\">",
"      Gardner LS, Ormond PJ. Treatment of multiple giant molluscum contagiosum in a renal transplant patient with imiquimod 5% cream. Clin Exp Dermatol 2006; 31:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/73\">",
"      Hourihane J, Hodges E, Smith J, et al. Interferon alpha treatment of molluscum contagiosum in immunodeficiency. Arch Dis Child 1999; 80:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/74\">",
"      B&ouml;hm M, Luger TA, Bonsmann G. Disseminated giant molluscum contagiosum in a patient with idiopathic CD4+ lymphocytopenia. Successful eradication with systemic interferon. Dermatology 2008; 217:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/75\">",
"      Kilic SS, Kilicbay F. Interferon-alpha treatment of molluscum contagiosum in a patient with hyperimmunoglobulin E syndrome. Pediatrics 2006; 117:e1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/76\">",
"      Nelson MR, Chard S, Barton SE. Intralesional interferon for the treatment of recalcitrant molluscum contagiosum in HIV antibody positive individuals--a preliminary report. Int J STD AIDS 1995; 6:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/77\">",
"      Ibarra V, Blanco JR, Oteo JA, Rosel L. Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm Venereol 2000; 80:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/78\">",
"      Meadows KP, Tyring SK, Pavia AT, Rallis TM. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997; 133:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/79\">",
"      Erickson C, Driscoll M, Gaspari A. Efficacy of intravenous cidofovir in the treatment of giant molluscum contagiosum in a patient with human immunodeficiency virus. Arch Dermatol 2011; 147:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/80\">",
"      Zabawski EJ Jr, Cockerell CJ. Topical cidofovir for molluscum contagiosum in children. Pediatr Dermatol 1999; 16:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/81\">",
"      Baxter KF, Highet AS. Topical cidofovir and cryotherapy--combination treatment for recalcitrant molluscum contagiosum in a patient with HIV infection. J Eur Acad Dermatol Venereol 2004; 18:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/82\">",
"      Toro JR, Wood LV, Patel NK, Turner ML. Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1. Arch Dermatol 2000; 136:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/83\">",
"      Bachmeyer C, Moguelet P, Baud F, Lescure FX. Efflorescence of facial molluscum contagiosum as a manifestation of immune reconstitution inflammatory syndrome in a patient with AIDS. Eur J Dermatol 2009; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/84\">",
"      Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosum in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with ritonavir. Clin Infect Dis 1997; 24:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/85\">",
"      Connell CO, Oranje A, Van Gysel D, Silverberg NB. Congenital molluscum contagiosum: report of four cases and review of the literature. Pediatr Dermatol 2008; 25:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/86\">",
"      Koning S, Bruijnzeels MA, van Suijlekom-Smit LW, van der Wouden JC. Molluscum contagiosum in Dutch general practice. Br J Gen Pract 1994; 44:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/43/6842/abstract/87\">",
"      Kyriakis KP, Palamaras I, Terzoudi S, et al. Case detection rates of molluscum contagiosum in childhood. Pediatr Dermatol 2007; 24:198.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4033 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-09F22AFDA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6842=[""].join("\n");
var outline_f6_43_6842=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8725830\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106808343\">",
"      ASSOCIATED CLINICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106808350\">",
"      Molluscum dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106808357\">",
"      Inflamed lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H106808364\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3760193\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H106808223\">",
"      LABORATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H797788\">",
"      Decision to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H797795\">",
"      Periocular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5283428\">",
"      FIRST-LINE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421447\">",
"      Cryotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421454\">",
"      Curettage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421482\">",
"      Cantharidin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5283409\">",
"      Podophyllotoxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5283833\">",
"      SECOND-LINE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421647\">",
"      Imiquimod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284164\">",
"      Potassium hydroxide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5283994\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284684\">",
"      Salicylic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5284328\">",
"      Topical retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H422717\">",
"      Other topical agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5283552\">",
"      Other physical interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421654\">",
"      Oral cimetidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H421668\">",
"      COMPARATIVE STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5282851\">",
"      IMMUNOCOMPROMISED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421689\">",
"      Interferon alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H421696\">",
"      Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H797087\">",
"      HAART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H421762\">",
"      SCHOOL AND SPORTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H421776\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8725830\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4033|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/9/13461\" title=\"picture 1A\">",
"      Molluscum on face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/12/12482\" title=\"picture 1B\">",
"      Molluscum face 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/31/16882\" title=\"picture 1C\">",
"      Molluscum neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/29/11734\" title=\"picture 1D\">",
"      Molluscum penis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/50/7974\" title=\"picture 1E\">",
"      Molluscum penis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/54/20323\" title=\"picture 1F\">",
"      Molluscum and eczema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/35/29233\" title=\"picture 2A\">",
"      Molluscum eyelid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/25/10643\" title=\"picture 2B\">",
"      Molluscum conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/28/44485\" title=\"picture 3A\">",
"      Molluscum in AIDS 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/16/13572\" title=\"picture 3B\">",
"      Molluscum in AIDS 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/47/31475\" title=\"picture 4\">",
"      Molluscum dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/9/10385\" title=\"picture 5\">",
"      Gianotti Crosti",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/12/17600\" title=\"picture 6\">",
"      Typical molluscum bumps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/19/28983\" title=\"picture 7\">",
"      Molluscum pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/14/10470\" title=\"picture 8A\">",
"      Cryptococcosis skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/15/35058\" title=\"picture 8B\">",
"      Disseminated cryptococcosis - papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/9/42132\" title=\"picture 8C\">",
"      Disseminated histoplasmosis - papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/24/16770\" title=\"picture 8D\">",
"      Penicillium marneffei - papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/46/10980\" title=\"picture 8E\">",
"      Penicillium marneffei papule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/57/32657\" title=\"picture 9\">",
"      Condylomata lata",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/19/23859\" title=\"picture 10\">",
"      Pyogenic granuloma - chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/56/4997\" title=\"picture 11\">",
"      Langerhans histiocytosis skin 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/22/16739\" title=\"picture 12\">",
"      Basal cell carcinoma eyelid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 1\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/8/13449?source=related_link\">",
"      Cryptococcal infection outside the central nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/33/33302?source=related_link\">",
"      Epidemiology and clinical manifestations of Penicillium marneffei infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23097?source=related_link\">",
"      Gianotti-Crosti syndrome (papular acrodermatitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/3/16439?source=related_link\">",
"      Monkeypox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/6/43112?source=related_link\">",
"      Pathogenesis and clinical manifestations of disseminated histoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/35/43583?source=related_link\">",
"      Patient information: Molluscum contagiosum (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35797?source=related_link\">",
"      The epidemiology, pathogenesis, and clinical manifestations of smallpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_43_6843="Fecundity with clomiphene treatment";
var content_f6_43_6843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71247&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cycle fecundity with clomiphene treatment",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fecundity, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anovulatory women who respond to treatment",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anovulatory women who respond to treatment and have no other infertility factors",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with unexplained infertility",
"       </td>",
"       <td>",
"        3.4 to 8.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Women with unexplained infertility treated with clomiphene and IUI",
"       </td>",
"       <td>",
"        8.5 to 9.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2003; 80:1302.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6843=[""].join("\n");
var outline_f6_43_6843=null;
var title_f6_43_6844="Pegasys Copegus dose mod";
var content_f6_43_6844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PEGASYS (peginterferon)/COPEGUS (ribavirin) dosage modification guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Laboratory values",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Discontinue if:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        PEGASYS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANC &ge;750/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Maintain 180 mcg",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         ANC &lt;500/mm",
"         <sup>",
"          3",
"         </sup>",
"         , treatment should be suspended until ANC values return to more than 1000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"        <p>",
"         Reinstitute at 90&nbsp;mcg and monitor ANC",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        ANC &lt;750/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Reduce to 135 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelet &ge;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Maintain 180 mcg",
"       </td>",
"       <td rowspan=\"2\">",
"        Platelet count &lt;25,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelet &lt;50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        Reduce to 90 mcg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        COPEGUS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin in patients with no cardiac disease",
"       </td>",
"       <td>",
"        Reduce to 600 mg/day* if &lt;10 g/dL",
"       </td>",
"       <td>",
"        &lt;8.5 g/dL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin in patients with history of stable cardiac disease",
"       </td>",
"       <td>",
"        Reduce to 600 mg/day* if &ge;2 g/dL decrease in hemoglobin during any 4-week period treatment",
"       </td>",
"       <td>",
"        &lt;12 g/dL despite 4 weeks at reduced dose",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * One 200 mg tablet in the morning and two 200 mg tablets in the evening.",
"    </div>",
"    <div class=\"reference\">",
"     Table from: Pegasys (peginterferon alfa-2a) Prescribing Information and Medication Guide. Roche Pharmaceuticals, Nutley, NJ. Available online at: file://www.rocheusa.com/products/pegasys/pi.pdf (Accessed on September 4, 2007).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6844=[""].join("\n");
var outline_f6_43_6844=null;
var title_f6_43_6845="Food frequency questionnaire";
var content_f6_43_6845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F69381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F69381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Food frequency questionnaire",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        How often does patient consume?",
"       </td>",
"       <td class=\"subtitle1\">",
"        MD evaluation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended amount",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fish",
"       </td>",
"       <td>",
"        How often is fish consumed?",
"       </td>",
"       <td>",
"        One or more times per week, emphasize fatty fish, encourage variety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meat",
"       </td>",
"       <td>",
"        Lean, trimmed?",
"       </td>",
"       <td>",
"        &lt;3 to 6 oz/day, as appropriate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poultry",
"       </td>",
"       <td>",
"        Which part of the chicken?",
"       </td>",
"       <td>",
"        &lt;3 to 6 oz skinless white meat or thigh meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Legumes",
"       </td>",
"       <td>",
"        Meat alternatives, dried beans, etc",
"       </td>",
"       <td>",
"        several times per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruit",
"       </td>",
"       <td>",
"        Variety? (not just bananas)",
"       </td>",
"       <td>",
"        2 to 3 per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetables",
"       </td>",
"       <td>",
"        Variety? (not just potatoes and corn)",
"       </td>",
"       <td>",
"        Volume should be half of the day's intake, 2 to 3 cups per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grains",
"       </td>",
"       <td>",
"        How much from white flour, pasta?",
"       </td>",
"       <td>",
"        4 to 6 servings of whole grains per day, including cereal, pasta, breads, rice and other whole grains",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dairy",
"       </td>",
"       <td>",
"        What percent milk fat? Cheese?",
"       </td>",
"       <td>",
"        Choose skim milk, lower-fat cheeses, exercise portion control",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"       <td>",
"        Added salt, canned foods, processed foods, cheese, sauces, condiments, restaurants and take out",
"       </td>",
"       <td>",
"        2 g sodium diet (less for certain conditions), NO added salt, less processed foods and cheese, decreased portions at restaurants, buy low-sodium options",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nuts, seeds, good fats",
"       </td>",
"       <td>",
"        Ground flax, pumpkin, walnuts, other nuts and seeds, avocado, olive or canola oils",
"       </td>",
"       <td>",
"        ~per day: 1/4 cup nuts or one small handful, or two tablespoons good oils, or&nbsp;two tablespoons ground flaxseed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Added fats",
"       </td>",
"       <td>",
"        Cream, cheese,&nbsp;butter, oils, sauces",
"       </td>",
"       <td>",
"        Choose small amounts of unsaturated, trans-fat-free additions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beverages",
"       </td>",
"       <td>",
"        Soda, juices, caloric beverages",
"       </td>",
"       <td>",
"        Avoid regular use of sweetened beverages, water down juices, caffeine in moderation, increase water instead of caloric beverages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Alcohol",
"       </td>",
"       <td rowspan=\"2\">",
"        Is intake appropriate?",
"       </td>",
"       <td>",
"        Men: &lt;2 drinks/day, women: &lt;1 drink/day; one drink is defined as 12 oz of regular beer, 5 oz of wine (12 percent alcohol), or 1.5 oz of 80-proof distilled spirits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minimal amounts best for patient with elevated triglycerides, diabetes, or hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water",
"       </td>",
"       <td>",
"        Is intake appropriate?",
"       </td>",
"       <td>",
"        Fluid intake guided by thirst, except in patients with known impairment of the thirst mechanism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fried foods",
"       </td>",
"       <td>",
"        Ask about preparation",
"       </td>",
"       <td>",
"        Encourage broiling, baking, saut&eacute;ing, boiling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restaurant fare or take out",
"       </td>",
"       <td>",
"        How many times/week or month?",
"       </td>",
"       <td>",
"        Encourage patient to request more vegetables, specify healthy food preparation methods, portion control is essential, and ask for low-sodium options",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6845=[""].join("\n");
var outline_f6_43_6845=null;
var title_f6_43_6846="KtV URR and dialysis survival";
var content_f6_43_6846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F77222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F77222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relative risk of mortality by dialysis dose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 317px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relative risk of mortality by delivered dose of dialysis as measured by quintiles of Kt/V (top panel) or urea reduction ratio (bottom panel, in percent) among a random sample of 2311 patients on dialysis for more than one year at the end of 1990. Increasing the dialysis dose improved survival with apparent maximum benefit at a Kt/V of 1.3 and urea reduction ratio of 70.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Held, PJ, Port, FK, Wolfe, RA, Kidney Int 1996; 50:550.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6846=[""].join("\n");
var outline_f6_43_6846=null;
var title_f6_43_6847="Transverse metacarpal shaft fracture";
var content_f6_43_6847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76416&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proximal transverse metacarpal shaft fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This oblique radiograph shows a proximal transverse fracture of the&nbsp;second metacarpal shaft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Josh Bloom, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_43_6847=[""].join("\n");
var outline_f6_43_6847=null;
